{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T15:04:49Z","timestamp":1793459089978,"version":"4.5.0"},"reference-count":282,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T00:00:00Z","timestamp":1726099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T00:00:00Z","timestamp":1726099200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the National Key Plan for Scientific Research and Development of China","award":["2021YFC2501204"],"award-info":[{"award-number":["2021YFC2501204"]}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81873785"],"award-info":[{"award-number":["81873785"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82071439"],"award-info":[{"award-number":["82071439"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81974202"],"award-info":[{"award-number":["81974202"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["U20A20355"],"award-info":[{"award-number":["U20A20355"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Technology Major Project of Hunan Provincial Science and Technology Department","award":["2021SK1010"],"award-info":[{"award-number":["2021SK1010"]}],"id":[{"id":"https:\/\/ror.org\/04qgr7x96","id-type":"ROR","asserted-by":"crossref"}]},{"name":"the Innovation-driven Team Project from Central South University","award":["2020CX016"],"award-info":[{"award-number":["2020CX016"]}],"id":[{"id":"https:\/\/ror.org\/00f1zfq44","id-type":"ROR","asserted-by":"crossref"}]},{"name":"the innovative team program from the Department of Science & Technology of Hunan Province","award":["2019RS1010"],"award-info":[{"award-number":["2019RS1010"]}],"id":[{"id":"https:\/\/ror.org\/04qgr7x96","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl Neurodegener"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Parkinson\u2019s disease (PD) is the second most common neurodegenerative disease. The development of PD is closely linked to genetic and environmental factors, with\n                    <jats:italic>GBA1<\/jats:italic>\n                    variants being the most common genetic risk. Mutations in the\n                    <jats:italic>GBA1<\/jats:italic>\n                    gene lead to reduced activity of the coded enzyme, glucocerebrosidase, which mediates the development of PD by affecting lipid metabolism (especially sphingolipids), lysosomal autophagy, endoplasmic reticulum, as well as\u00a0mitochondrial and other cellular functions. Clinically, PD with\n                    <jats:italic>GBA1<\/jats:italic>\n                    mutations (\n                    <jats:italic>GBA1<\/jats:italic>\n                    -PD) is characterized by particular features regarding the progression of symptom severity. On the therapeutic side, the discovery of the relationship between\n                    <jats:italic>GBA1<\/jats:italic>\n                    variants and PD offers an opportunity for targeted therapeutic interventions. In this review, we explore the genotypic and phenotypic correlations, etiologic mechanisms, biomarkers, and therapeutic approaches of\n                    <jats:italic>GBA1<\/jats:italic>\n                    -PD and summarize the current state of research and its challenges.\n                  <\/jats:p>","DOI":"10.1186\/s40035-024-00437-6","type":"journal-article","created":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T00:02:34Z","timestamp":1726099354000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":64,"title":["Clinical, mechanistic, biomarker, and therapeutic advances in GBA1-associated Parkinson\u2019s disease"],"prefix":"10.1186","volume":"13","author":[{"given":"Xuxiang","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beisha","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3658-3928","authenticated-orcid":false,"given":"Jifeng","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,12]]},"reference":[{"issue":"10423","key":"437_CR1","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/S0140-6736(23)01478-2","volume":"403","author":"HR Morris","year":"2024","unstructured":"Morris HR, Spillantini MG, Sue CM, Williams-Gray CH. The pathogenesis of Parkinson\u2019s disease. Lancet. 2024;403(10423):293\u2013304.","journal-title":"Lancet"},{"issue":"2","key":"437_CR2","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/S1474-4422(19)30287-X","volume":"19","author":"C Blauwendraat","year":"2020","unstructured":"Blauwendraat C, Nalls MA, Singleton AB. The genetic architecture of Parkinson\u2019s disease. Lancet Neurol. 2020;19(2):170\u20138.","journal-title":"Lancet Neurol"},{"key":"437_CR3","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1146\/annurev-pathmechdis-031521-034145","volume":"18","author":"H Ye","year":"2023","unstructured":"Ye H, Robak LA, Yu M, Cykowski M, Shulman JM. Genetics and pathogenesis of Parkinson\u2019s syndrome. Annu Rev Pathol. 2023;18:95\u2013121.","journal-title":"Annu Rev Pathol"},{"issue":"11","key":"437_CR4","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/S1474-4422(23)00283-1","volume":"22","author":"M Rizig","year":"2023","unstructured":"Rizig M, Bandres-Ciga S, Makarious MB, Ojo OO, Crea PW, Abiodun OV, et al. Identification of genetic risk loci and causal insights associated with Parkinson\u2019s disease in African and African admixed populations: a genome-wide association study. Lancet Neurol. 2023;22(11):1015\u201325.","journal-title":"Lancet Neurol"},{"issue":"1","key":"437_CR5","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41588-023-01584-8","volume":"56","author":"JJ Kim","year":"2024","unstructured":"Kim JJ, Vitale D, Otani DV, Lian MM, Heilbron K, et al. Multi-ancestry genome-wide association meta-analysis of Parkinson\u2019s disease. Nat Genet. 2024;56(1):27\u201336.","journal-title":"Nat Genet"},{"issue":"6","key":"437_CR6","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1001\/jamaneurol.2020.0428","volume":"77","author":"JN Foo","year":"2020","unstructured":"Foo JN, Chew EGY, Chung SJ, Peng R, Blauwendraat C, Nalls MA, et al. Identification of risk loci for Parkinson disease in Asians and comparison of risk between Asians and Europeans: a genome-wide association study. JAMA Neurol. 2020;77(6):746\u201354.","journal-title":"JAMA Neurol"},{"issue":"12","key":"437_CR7","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/S1474-4422(19)30320-5","volume":"18","author":"MA Nalls","year":"2019","unstructured":"Nalls MA, Blauwendraat C, Vallerga CL, Heilbron K, Bandres-Ciga S, Chang D, et al. Identification of novel risk loci, causal insights, and heritable risk for Parkinson\u2019s disease: a meta-analysis of genome-wide association studies. Lancet Neurol. 2019;18(12):1091\u2013102.","journal-title":"Lancet Neurol"},{"issue":"3","key":"437_CR8","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s00401-020-02181-3","volume":"140","author":"S Bandres-Ciga","year":"2020","unstructured":"Bandres-Ciga S, Saez-Atienzar S, Kim JJ, Makarious MB, Faghri F, Diez-Fairen M, et al. Large-scale pathway specific polygenic risk and transcriptomic community network analysis identifies novel functional pathways in Parkinson disease. Acta Neuropathol. 2020;140(3):341\u201358.","journal-title":"Acta Neuropathol"},{"issue":"3","key":"437_CR9","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.tins.2021.12.004","volume":"45","author":"V Udayar","year":"2022","unstructured":"Udayar V, Chen Y, Sidransky E, Jagasia R. Lysosomal dysfunction in neurodegeneration: emerging concepts and methods. Trends Neurosci. 2022;45(3):184\u201399.","journal-title":"Trends Neurosci"},{"issue":"12","key":"437_CR10","doi-asserted-by":"publisher","first-page":"3191","DOI":"10.1093\/brain\/awx285","volume":"140","author":"LA Robak","year":"2017","unstructured":"Robak LA, Jansen IE, van Rooij J, Uitterlinden AG, Kraaij R, Jankovic J, et al. Excessive burden of lysosomal storage disorder gene variants in Parkinson\u2019s disease. Brain. 2017;140(12):3191\u2013203.","journal-title":"Brain"},{"key":"437_CR11","doi-asserted-by":"publisher","first-page":"114402","DOI":"10.1016\/j.addr.2022.114402","volume":"187","author":"M Horowitz","year":"2022","unstructured":"Horowitz M, Braunstein H, Zimran A, Revel-Vilk S, Goker-Alpan O. Lysosomal functions and dysfunctions: Molecular and cellular mechanisms underlying Gaucher disease and its association with Parkinson disease. Adv Drug Deliv Rev. 2022;187:114402.","journal-title":"Adv Drug Deliv Rev"},{"issue":"8","key":"437_CR12","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.3390\/brainsci13081212","volume":"13","author":"A Droby","year":"2023","unstructured":"Droby A, Thaler A, Mirelman A. Imaging markers in genetic forms of Parkinson\u2019s disease. Brain Sci. 2023;13(8):1212.","journal-title":"Brain Sci"},{"issue":"9645","key":"437_CR13","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/S0140-6736(08)61522-6","volume":"372","author":"GA Grabowski","year":"2008","unstructured":"Grabowski GA. Phenotype, diagnosis, and treatment of Gaucher\u2019s disease. Lancet. 2008;372(9645):1263\u201371.","journal-title":"Lancet"},{"issue":"5","key":"437_CR14","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1002\/mds.28496","volume":"36","author":"M Avenali","year":"2021","unstructured":"Avenali M, Cerri S, Ongari G, Ghezzi C, Pacchetti C, Tassorelli C, et al. Profiling the biochemical signature of GBA-related Parkinson\u2019s disease in peripheral blood mononuclear cells. Mov Disord. 2021;36(5):1267\u201372.","journal-title":"Mov Disord"},{"issue":"1","key":"437_CR15","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s13041-020-00712-3","volume":"14","author":"R Thomas","year":"2021","unstructured":"Thomas R, Moloney EB, Macbain ZK, Hallett PJ, Isacson O. Fibroblasts from idiopathic Parkinson\u2019s disease exhibit deficiency of lysosomal glucocerebrosidase activity associated with reduced levels of the trafficking receptor LIMP2. Mol Brain. 2021;14(1):16.","journal-title":"Mol Brain"},{"issue":"4","key":"437_CR16","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.cell.2007.10.018","volume":"131","author":"D Reczek","year":"2007","unstructured":"Reczek D, Schwake M, Schroder J, Hughes H, Blanz J, Jin X, et al. LIMP-2 is a receptor for lysosomal mannose-6-phosphate-independent targeting of beta-glucocerebrosidase. Cell. 2007;131(4):770\u201383.","journal-title":"Cell"},{"issue":"1","key":"437_CR17","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41368-023-00229-0","volume":"15","author":"Y Liu","year":"2023","unstructured":"Liu Y, Li S, Wang S, Yang Q, Wu Z, Zhang M, et al. LIMP-2 enhances cancer stem-like cell properties by promoting autophagy-induced GSK3beta degradation in head and neck squamous cell carcinoma. Int J Oral Sci. 2023;15(1):24.","journal-title":"Int J Oral Sci"},{"issue":"6","key":"437_CR18","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.tcb.2020.02.007","volume":"30","author":"Y Meng","year":"2020","unstructured":"Meng Y, Heybrock S, Neculai D, Saftig P. Cholesterol handling in lysosomes and beyond. Trends Cell Biol. 2020;30(6):452\u201366.","journal-title":"Trends Cell Biol"},{"issue":"3","key":"437_CR19","doi-asserted-by":"publisher","first-page":"ar42","DOI":"10.1091\/mbc.E23-06-0251","volume":"35","author":"J Ecard","year":"2024","unstructured":"Ecard J, Lian YL, Divoux S, Gouveia Z, Vigne E, Perez F, et al. Lysosomal membrane proteins LAMP1 and LIMP2 are segregated in the Golgi apparatus independently of their clathrin adaptor binding motif. Mol Biol Cell. 2024;35(3):ar42.","journal-title":"Mol Biol Cell"},{"issue":"2","key":"437_CR20","doi-asserted-by":"publisher","first-page":"241","DOI":"10.4161\/auto.22557","volume":"9","author":"M Tatti","year":"2013","unstructured":"Tatti M, Motta M, Di Bartolomeo S, Cianfanelli V, Salvioli R. Cathepsin-mediated regulation of autophagy in saposin C deficiency. Autophagy. 2013;9(2):241\u20133.","journal-title":"Autophagy"},{"issue":"20","key":"437_CR21","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1056\/NEJMicm2116167","volume":"386","author":"L Suner","year":"2022","unstructured":"Suner L, Delhommeau F. Gaucher\u2019s disease. N Engl J Med. 2022;386(20):1932.","journal-title":"N Engl J Med"},{"key":"437_CR22","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.cytogfr.2018.04.003","volume":"41","author":"Y Chen","year":"2018","unstructured":"Chen Y, Sud N, Hettinghouse A, Liu CJ. Molecular regulations and therapeutic targets of Gaucher disease. Cytokine Growth Factor Rev. 2018;41:65\u201374.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"Pt B","key":"437_CR23","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.expneurol.2017.09.010","volume":"298","author":"L Smith","year":"2017","unstructured":"Smith L, Mullin S, Schapira AHV. Insights into the structural biology of Gaucher disease. Exp Neurol. 2017;298(Pt B):180\u201390.","journal-title":"Exp Neurol"},{"key":"437_CR24","doi-asserted-by":"publisher","first-page":"108419","DOI":"10.1016\/j.pharmthera.2023.108419","volume":"246","author":"E Menozzi","year":"2023","unstructured":"Menozzi E, Toffoli M, Schapira AHV. Targeting the GBA1 pathway to slow Parkinson disease: insights into clinical aspects, pathogenic mechanisms and new therapeutic avenues. Pharmacol Ther. 2023;246:108419.","journal-title":"Pharmacol Ther"},{"issue":"1","key":"437_CR25","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13024-019-0336-2","volume":"14","author":"J Do","year":"2019","unstructured":"Do J, McKinney C, Sharma P, Sidransky E. Glucocerebrosidase and its relevance to Parkinson disease. Mol Neurodegener. 2019;14(1):36.","journal-title":"Mol Neurodegener"},{"key":"437_CR26","doi-asserted-by":"publisher","first-page":"105663","DOI":"10.1016\/j.nbd.2022.105663","volume":"166","author":"ME Gegg","year":"2022","unstructured":"Gegg ME, Menozzi E, Schapira AHV. Glucocerebrosidase-associated Parkinson disease: pathogenic mechanisms and potential drug treatments. Neurobiol Dis. 2022;166:105663.","journal-title":"Neurobiol Dis"},{"key":"437_CR27","doi-asserted-by":"publisher","first-page":"106534","DOI":"10.1016\/j.bpc.2020.106534","volume":"273","author":"SS Munoz","year":"2021","unstructured":"Munoz SS, Petersen D, Marlet FR, Kucukkose E, Galvagnion C. The interplay between glucocerebrosidase, alpha-synuclein and lipids in human models of Parkinson\u2019s disease. Biophys Chem. 2021;273:106534.","journal-title":"Biophys Chem"},{"issue":"2","key":"437_CR28","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1001\/jamaneurol.2014.2950","volume":"72","author":"M Beavan","year":"2015","unstructured":"Beavan M, McNeill A, Proukakis C, Hughes DA, Mehta A, Schapira AH. Evolution of prodromal clinical markers of Parkinson disease in a GBA mutation-positive cohort. JAMA Neurol. 2015;72(2):201\u20138.","journal-title":"JAMA Neurol"},{"key":"437_CR29","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.3389\/fgene.2019.01297","volume":"10","author":"Z Hanss","year":"2019","unstructured":"Hanss Z, Boussaad I, Jarazo J, Schwamborn JC, Kruger R. Quality control strategy for CRISPR-Cas9-based gene editing complicated by a pseudogene. Front Genet. 2019;10:1297.","journal-title":"Front Genet"},{"issue":"1","key":"437_CR30","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/s42003-022-03577-5","volume":"5","author":"K Miyoshi","year":"2022","unstructured":"Miyoshi K, Hagita H, Horiguchi T, Tanimura A, Noma T. Redefining GBA gene structure unveils the ability of Cap-independent, IRES-dependent gene regulation. Commun Biol. 2022;5(1):639.","journal-title":"Commun Biol"},{"issue":"1","key":"437_CR31","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1002\/mds.26845","volume":"32","author":"N Spataro","year":"2017","unstructured":"Spataro N, Roca-Umbert A, Cervera-Carles L, Valles M, Anglada R, Pagonabarraga J, et al. Detection of genomic rearrangements from targeted resequencing data in Parkinson\u2019s disease patients. Mov Disord. 2017;32(1):165\u20139.","journal-title":"Mov Disord"},{"key":"437_CR32","doi-asserted-by":"publisher","unstructured":"Tayebi N, Lichtenberg J, Hertz E, Sidransky E. Is Gauchian genotyping of GBA1 variants reliable? medRxiv. 2023:2023.10.26.23297627. https:\/\/doi.org\/10.1101\/2023.10.26.23297627.","DOI":"10.1101\/2023.10.26.23297627"},{"issue":"1","key":"437_CR33","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1038\/s42003-022-03610-7","volume":"5","author":"M Toffoli","year":"2022","unstructured":"Toffoli M, Chen X, Sedlazeck FJ, Lee CY, Mullin S, Higgins A, et al. Comprehensive short and long read sequencing analysis for the Gaucher and Parkinson\u2019s disease-associated GBA gene. Commun Biol. 2022;5(1):670.","journal-title":"Commun Biol"},{"issue":"1","key":"437_CR34","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1186\/s13023-022-02573-6","volume":"17","author":"A Dardis","year":"2022","unstructured":"Dardis A, Michelakakis H, Rozenfeld P, Fumic K, Wagner J, Pavan E, et al. Patient centered guidelines for the laboratory diagnosis of Gaucher disease type 1. Orphanet J Rare Dis. 2022;17(1):442.","journal-title":"Orphanet J Rare Dis"},{"issue":"21","key":"437_CR35","doi-asserted-by":"publisher","first-page":"4890","DOI":"10.3390\/jcm10214890","volume":"10","author":"A Jezela-Stanek","year":"2021","unstructured":"Jezela-Stanek A, Kleinotiene G, Chwialkowska K, Tylki-Szymanska A. Do not miss the (genetic) diagnosis of Gaucher syndrome: a narrative review on diagnostic clues and management in severe prenatal and perinatal-lethal sporadic cases. J Clin Med. 2021;10(21):4890.","journal-title":"J Clin Med"},{"issue":"5","key":"437_CR36","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1002\/humu.20676","volume":"29","author":"KS Hruska","year":"2008","unstructured":"Hruska KS, LaMarca ME, Scott CR, Sidransky E. Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA). Hum Mutat. 2008;29(5):567\u201383.","journal-title":"Hum Mutat"},{"issue":"1","key":"437_CR37","doi-asserted-by":"publisher","first-page":"12702","DOI":"10.1038\/s41598-017-12973-5","volume":"7","author":"L Straniero","year":"2017","unstructured":"Straniero L, Rimoldi V, Samarani M, Goldwurm S, Di Fonzo A, Kruger R, et al. The GBAP1 pseudogene acts as a ceRNA for the glucocerebrosidase gene GBA by sponging miR-22-3p. Sci Rep. 2017;7(1):12702.","journal-title":"Sci Rep"},{"issue":"9","key":"437_CR38","doi-asserted-by":"publisher","first-page":"6754","DOI":"10.1007\/s12035-024-04008-8","volume":"61","author":"JCC Dos Santos","year":"2024","unstructured":"Dos Santos JCC, Mano GBC, da Cunha Barreto-Vianna AR, Garcia TFM, de Vasconcelos AV, Sa CSG, et al. The molecular impact of glucosylceramidase beta 1 (Gba1) in Parkinson's disease: a new genetic state of the art. Mol Neurobiol. 2024;61(9):6754\u201370.","journal-title":"Mol Neurobiol"},{"key":"437_CR39","doi-asserted-by":"publisher","first-page":"684067","DOI":"10.3389\/fgene.2021.684067","volume":"12","author":"EG Woo","year":"2021","unstructured":"Woo EG, Tayebi N, Sidransky E. Next-generation sequencing analysis of GBA1: the challenge of detecting complex recombinant alleles. Front Genet. 2021;12:684067.","journal-title":"Front Genet"},{"issue":"1","key":"437_CR40","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/s41531-023-00595-w","volume":"9","author":"S Pachchek","year":"2023","unstructured":"Pachchek S, Landoulsi Z, Pavelka L, Schulte C, Buena-Atienza E, Gross C, et al. Accurate long-read sequencing identified GBA1 as major risk factor in the Luxembourgish Parkinson\u2019s study. NPJ Parkinsons Dis. 2023;9(1):156.","journal-title":"NPJ Parkinsons Dis"},{"issue":"2","key":"437_CR41","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1136\/jnnp.48.2.172","volume":"48","author":"RO McKeran","year":"1985","unstructured":"McKeran RO, Bradbury P, Taylor D, Stern G. Neurological involvement in type 1 (adult) Gaucher\u2019s disease. J Neurol Neurosurg Psychiatry. 1985;48(2):172\u20135.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"437_CR42","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/S1474-4422(23)00283-1","volume":"22","author":"M Rizig","year":"2023","unstructured":"Rizig M, Bandres-Ciga S, Makarious MB, Ojo OO, Crea PW, Abiodun OV, et al. Identification of genetic risk loci and causal insights associated with Parkinson\u2019s disease in African and African admixed populations: a genome-wide association study. Lancet Neurol. 2023;22:1015\u201325.","journal-title":"Lancet Neurol"},{"issue":"6","key":"437_CR43","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1001\/jamaneurol.2014.313","volume":"71","author":"RN Alcalay","year":"2014","unstructured":"Alcalay RN, Dinur T, Quinn T, Sakanaka K, Levy O, Waters C, et al. Comparison of Parkinson risk in Ashkenazi Jewish patients with Gaucher disease and GBA heterozygotes. JAMA Neurol. 2014;71(6):752\u20137.","journal-title":"JAMA Neurol"},{"issue":"7","key":"437_CR44","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1056\/NEJM200502173520719","volume":"352","author":"MJ Eblan","year":"2005","unstructured":"Eblan MJ, Walker JM, Sidransky E. The glucocerebrosidase gene and Parkinson\u2019s disease in Ashkenazi Jews. N Engl J Med. 2005;352(7):728\u201331 (author reply 728\u201331).","journal-title":"N Engl J Med"},{"issue":"17","key":"437_CR45","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1056\/NEJMoa0901281","volume":"361","author":"E Sidransky","year":"2009","unstructured":"Sidransky E, Nalls MA, Aasly JO, Aharon-Peretz J, Annesi G, Barbosa ER, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson\u2019s disease. N Engl J Med. 2009;361(17):1651\u201361.","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"437_CR46","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/jnc.13385","volume":"139","author":"A Migdalska-Richards","year":"2016","unstructured":"Migdalska-Richards A, Schapira AH. The relationship between glucocerebrosidase mutations and Parkinson disease. J Neurochem. 2016;139(Suppl 1):77\u201390.","journal-title":"J Neurochem"},{"issue":"1","key":"437_CR47","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1093\/hmg\/ddq454","volume":"20","author":"S Lesage","year":"2011","unstructured":"Lesage S, Anheim M, Condroyer C, Pollak P, Durif F, Dupuits C, et al. Large-scale screening of the Gaucher\u2019s disease-related glucocerebrosidase gene in Europeans with Parkinson\u2019s disease. Hum Mol Genet. 2011;20(1):202\u201310.","journal-title":"Hum Mol Genet"},{"issue":"9","key":"437_CR48","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1212\/WNL.0000000000001315","volume":"84","author":"Z Gan-Or","year":"2015","unstructured":"Gan-Or Z, Amshalom I, Kilarski LL, Bar-Shira A, Gana-Weisz M, Mirelman A, et al. Differential effects of severe vs mild GBA mutations on Parkinson disease. Neurology. 2015;84(9):880\u20137.","journal-title":"Neurology"},{"issue":"3","key":"437_CR49","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1002\/mds.29314","volume":"38","author":"SC Parlar","year":"2023","unstructured":"Parlar SC, Grenn FP, Kim JJ, Baluwendraat C, Gan-Or Z. Classification of GBA1 variants in Parkinson\u2019s disease: the GBA1-PD browser. Mov Disord. 2023;38(3):489\u201395.","journal-title":"Mov Disord"},{"issue":"Pt 7","key":"437_CR50","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1093\/brain\/awp044","volume":"132","author":"J Neumann","year":"2009","unstructured":"Neumann J, Bras J, Deas E, O\u2019Sullivan SS, Parkkinen L, Lachmann RH, et al. Glucocerebrosidase mutations in clinical and pathologically proven Parkinson\u2019s disease. Brain. 2009;132(Pt 7):1783\u201394.","journal-title":"Brain"},{"key":"437_CR51","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3389\/fnmol.2018.00043","volume":"11","author":"Y Zhang","year":"2018","unstructured":"Zhang Y, Shu L, Sun Q, Zhou X, Pan H, Guo J, et al. Integrated Genetic analysis of racial differences of common GBA variants in Parkinson\u2019s disease: a meta-analysis. Front Mol Neurosci. 2018;11:43.","journal-title":"Front Mol Neurosci"},{"issue":"11","key":"437_CR52","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1002\/mds.28191","volume":"35","author":"Y Chen","year":"2020","unstructured":"Chen Y, Gu X, Ou R, Zhang L, Hou Y, Liu K, et al. Evaluating the role of SNCA, LRRK2, and GBA in Chinese patients with early-onset Parkinson\u2019s disease. Mov Disord. 2020;35(11):2046\u201355.","journal-title":"Mov Disord"},{"key":"437_CR53","doi-asserted-by":"publisher","first-page":"150 e5","DOI":"10.1016\/j.neurobiolaging.2019.12.023","volume":"90","author":"N Li","year":"2020","unstructured":"Li N, Wang L, Zhang J, Tan EK, Li J, Peng J, et al. Whole-exome sequencing in early-onset Parkinson\u2019s disease among ethnic Chinese. Neurobiol Aging. 2020;90:150 e5-150 e11.","journal-title":"Neurobiol Aging"},{"issue":"2","key":"437_CR54","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/jhg.2014.110","volume":"60","author":"Z Yu","year":"2015","unstructured":"Yu Z, Wang T, Xu J, Wang W, Wang G, Chen C, et al. Mutations in the glucocerebrosidase gene are responsible for Chinese patients with Parkinson\u2019s disease. J Hum Genet. 2015;60(2):85\u201390.","journal-title":"J Hum Genet"},{"issue":"7","key":"437_CR55","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1093\/brain\/awaa167","volume":"143","author":"Y Zhao","year":"2020","unstructured":"Zhao Y, Qin L, Pan H, Liu Z, Jiang L, He Y, et al. The role of genetics in Parkinson\u2019s disease: a large cohort study in Chinese mainland population. Brain. 2020;143(7):2220\u201334.","journal-title":"Brain"},{"issue":"9","key":"437_CR56","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/j.parkreldis.2014.06.007","volume":"20","author":"T Pulkes","year":"2014","unstructured":"Pulkes T, Choubtum L, Chitphuk S, Thakkinstian A, Pongpakdee S, Kulkantrakorn K, et al. Glucocerebrosidase mutations in Thai patients with Parkinson\u2019s disease. Parkinsonism Relat Disord. 2014;20(9):986\u201391.","journal-title":"Parkinsonism Relat Disord"},{"issue":"8","key":"437_CR57","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1002\/mds.23009","volume":"25","author":"QY Sun","year":"2010","unstructured":"Sun QY, Guo JF, Wang L, Yu RH, Zuo X, Yao LY, et al. Glucocerebrosidase gene L444P mutation is a risk factor for Parkinson\u2019s disease in Chinese population. Mov Disord. 2010;25(8):1005\u201311.","journal-title":"Mov Disord"},{"issue":"12","key":"437_CR58","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1001\/jamaneurol.2014.1909","volume":"71","author":"J Trinh","year":"2014","unstructured":"Trinh J, Guella I, Farrer MJ. Disease penetrance of late-onset Parkinsonism: a meta-analysis. JAMA Neurol. 2014;71(12):1535\u20139.","journal-title":"JAMA Neurol"},{"issue":"11","key":"437_CR59","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1002\/mds.28200","volume":"35","author":"R Balestrino","year":"2020","unstructured":"Balestrino R, Tunesi S, Tesei S, Lopiano L, Zecchinelli AL, Goldwurm S. Penetrance of glucocerebrosidase (GBA) mutations in Parkinson\u2019s disease: a Kin cohort study. Mov Disord. 2020;35(11):2111\u20134.","journal-title":"Mov Disord"},{"issue":"6","key":"437_CR60","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1212\/WNL.0b013e318245f476","volume":"78","author":"M Anheim","year":"2012","unstructured":"Anheim M, Elbaz A, Lesage S, Durr A, Condroyer C, Viallet F, et al. Penetrance of Parkinson disease in glucocerebrosidase gene mutation carriers. Neurology. 2012;78(6):417\u201320.","journal-title":"Neurology"},{"issue":"4","key":"437_CR61","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s11910-023-01259-1","volume":"23","author":"E Menozzi","year":"2023","unstructured":"Menozzi E, Schapira AHV, Blandini F, Avenali M. Who is at risk of Parkinson disease? Refining the preclinical phase of GBA1 and LRRK2 variant carriers: a clinical, biochemical, and imaging approach. Curr Neurol Neurosci Rep. 2023;23(4):121\u201330.","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"4","key":"437_CR62","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1002\/mds.27971","volume":"35","author":"S Ji","year":"2020","unstructured":"Ji S, Wang C, Qiao H, Gu Z, Gan-Or Z, Fon EA, et al. Decreased penetrance of Parkinson\u2019s disease in elderly carriers of glucocerebrosidase gene L444P\/R mutations: a community-based 10-year longitudinal study. Mov Disord. 2020;35(4):672\u20138.","journal-title":"Mov Disord"},{"issue":"1","key":"437_CR63","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1093\/brain\/awz350","volume":"143","author":"C Blauwendraat","year":"2020","unstructured":"Blauwendraat C, Reed X, Krohn L, Heilbron K, Bandres-Ciga S, Tan M, et al. Genetic modifiers of risk and age at onset in GBA associated Parkinson\u2019s disease and Lewy body dementia. Brain. 2020;143(1):234\u201348.","journal-title":"Brain"},{"issue":"5","key":"437_CR64","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1002\/mds.29342","volume":"38","author":"C Blauwendraat","year":"2023","unstructured":"Blauwendraat C, Tayebi N, Woo EG, Lopez G, Fierro L, Toffoli M, et al. Polygenic Parkinson\u2019s disease genetic risk score as risk modifier of Parkinsonism in Gaucher disease. Mov Disord. 2023;38(5):899\u2013903.","journal-title":"Mov Disord"},{"issue":"5","key":"437_CR65","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1136\/jmedgenet-2019-106283","volume":"57","author":"H Leonard","year":"2020","unstructured":"Leonard H, Blauwendraat C, Krohn L, Faghri F, Iwaki H, Ferguson G, et al. Genetic variability and potential effects on clinical trial outcomes: perspectives in Parkinson\u2019s disease. J Med Genet. 2020;57(5):331\u20138.","journal-title":"J Med Genet"},{"issue":"1","key":"437_CR66","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/s41531-023-00571-4","volume":"9","author":"Y Zhou","year":"2023","unstructured":"Zhou Y, Wang Y, Wan J, Zhao Y, Pan H, Zeng Q, et al. Mutational spectrum and clinical features of GBA1 variants in a Chinese cohort with Parkinson\u2019s disease. NPJ Parkinsons Dis. 2023;9(1):129.","journal-title":"NPJ Parkinsons Dis"},{"issue":"8","key":"437_CR67","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1001\/jamaneurol.2015.0703","volume":"72","author":"SM Fereshtehnejad","year":"2015","unstructured":"Fereshtehnejad SM, Romenets SR, Anang JB, Latreille V, Gagnon JF, Postuma RB. New clinical subtypes of Parkinson disease and their longitudinal progression: a prospective cohort comparison with other phenotypes. JAMA Neurol. 2015;72(8):863\u201373.","journal-title":"JAMA Neurol"},{"issue":"1","key":"437_CR68","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1002\/mds.28818","volume":"37","author":"SP Caminiti","year":"2022","unstructured":"Caminiti SP, Carli G, Avenali M, Blandini F, Perani D. Clinical and dopamine transporter imaging trajectories in a cohort of Parkinson\u2019s disease patients with GBA mutations. Mov Disord. 2022;37(1):106\u201318.","journal-title":"Mov Disord"},{"issue":"11","key":"437_CR69","doi-asserted-by":"publisher","first-page":"3218","DOI":"10.1111\/ene.15509","volume":"29","author":"YP Chen","year":"2022","unstructured":"Chen YP, Yu SH, Zhang GH, Hou YB, Gu XJ, Ou RW, et al. The mutation spectrum of Parkinson-disease-related genes in early-onset Parkinson\u2019s disease in ethnic Chinese. Eur J Neurol. 2022;29(11):3218\u201328.","journal-title":"Eur J Neurol"},{"issue":"7","key":"437_CR70","doi-asserted-by":"publisher","first-page":"e1036","DOI":"10.1212\/WNL.0000000000011411","volume":"96","author":"J Maple-Grodem","year":"2021","unstructured":"Maple-Grodem J, Dalen I, Tysnes OB, Macleod AD, Forsgren L, Counsell CE, et al. Association of GBA genotype with motor and functional decline in patients with newly diagnosed Parkinson disease. Neurology. 2021;96(7):e1036\u201344.","journal-title":"Neurology"},{"issue":"7","key":"437_CR71","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1136\/jnnp-2020-322857","volume":"91","author":"TB Stoker","year":"2020","unstructured":"Stoker TB, Camacho M, Winder-Rhodes S, Liu G, Scherzer CR, Foltynie T, et al. Impact of GBA1 variants on long-term clinical progression and mortality in incident Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry. 2020;91(7):695\u2013702.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"437_CR72","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.parkreldis.2016.12.014","volume":"36","author":"A Thaler","year":"2017","unstructured":"Thaler A, Gurevich T, Bar Shira A, Gana Weisz M, Ash E, Shiner T, et al. A \u201cdose\u201d effect of mutations in the GBA gene on Parkinson\u2019s disease phenotype. Parkinsonism Relat Disord. 2017;36:47\u201351.","journal-title":"Parkinsonism Relat Disord"},{"issue":"11","key":"437_CR73","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1002\/mds.28195","volume":"35","author":"S Petrucci","year":"2020","unstructured":"Petrucci S, Ginevrino M, Trezzi I, Monfrini E, Ricciardi L, Albanese A, et al. GBA-related Parkinson\u2019s disease: dissection of genotype-phenotype correlates in a large Italian cohort. Mov Disord. 2020;35(11):2106\u201311.","journal-title":"Mov Disord"},{"issue":"9","key":"437_CR74","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1002\/mds.27775","volume":"34","author":"S Mullin","year":"2019","unstructured":"Mullin S, Beavan M, Bestwick J, McNeill A, Proukakis C, Cox T, et al. Evolution and clustering of prodromal Parkinsonian features in GBA1 carriers. Mov Disord. 2019;34(9):1365\u201373.","journal-title":"Mov Disord"},{"issue":"1","key":"437_CR75","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/s41531-024-00706-1","volume":"10","author":"B Roeben","year":"2024","unstructured":"Roeben B, Liepelt-Scarfone I, Lerche S, Zimmermann M, Wurster I, Sunkel U, et al. Longitudinal cognitive decline characterizes the profile of non-PD-manifest GBA1 mutation carriers. NPJ Parkinsons Dis. 2024;10(1):88.","journal-title":"NPJ Parkinsons Dis"},{"key":"437_CR76","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.parkreldis.2018.08.007","volume":"57","author":"SY Liu","year":"2018","unstructured":"Liu SY, Zheng Z, Gu ZQ, Wang CD, Tang BS, Xu YM, et al. Prevalence of pre-diagnostic symptoms did not differ between LRRK2-related, GBA-related and idiopathic patients with Parkinson\u2019s disease. Parkinsonism Relat Disord. 2018;57:72\u20136.","journal-title":"Parkinsonism Relat Disord"},{"issue":"9","key":"437_CR77","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1002\/acn3.228","volume":"2","author":"Z Gan-Or","year":"2015","unstructured":"Gan-Or Z, Mirelman A, Postuma RB, Arnulf I, Bar-Shira A, Dauvilliers Y, et al. GBA mutations are associated with rapid eye movement sleep behavior disorder. Ann Clin Transl Neurol. 2015;2(9):941\u20135.","journal-title":"Ann Clin Transl Neurol"},{"issue":"1","key":"437_CR78","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1002\/mds.28792","volume":"37","author":"N Omer","year":"2022","unstructured":"Omer N, Giladi N, Gurevich T, Bar-Shira A, Gana-Weisz M, Glinka T, et al. Glucocerebrosidase activity is not associated with Parkinson\u2019s disease risk or severity. Mov Disord. 2022;37(1):190\u20135.","journal-title":"Mov Disord"},{"issue":"1","key":"437_CR79","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s40035-022-00294-1","volume":"11","author":"J Huang","year":"2022","unstructured":"Huang J, Cheng Y, Li C, Shang H. Genetic heterogeneity on sleep disorders in Parkinson\u2019s disease: a systematic review and meta-analysis. Transl Neurodegener. 2022;11(1):21.","journal-title":"Transl Neurodegener"},{"issue":"10","key":"437_CR80","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1136\/jnnp-2019-320394","volume":"90","author":"M Avenali","year":"2019","unstructured":"Avenali M, Toffoli M, Mullin S, McNeil A, Hughes DA, Mehta A, et al. Evolution of prodromal Parkinsonian features in a cohort of GBA mutation-positive individuals: a 6-year longitudinal study. J Neurol Neurosurg Psychiatry. 2019;90(10):1091\u20137.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"437_CR81","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s41531-022-00344-5","volume":"8","author":"R Morris","year":"2022","unstructured":"Morris R, Martini DN, Ramsey K, Kelly VE, Smulders K, Hiller A, et al. Cognition as a mediator for gait and balance impairments in GBA-related Parkinson\u2019s disease. NPJ Parkinsons Dis. 2022;8(1):78.","journal-title":"NPJ Parkinsons Dis"},{"key":"437_CR82","doi-asserted-by":"publisher","first-page":"1091919","DOI":"10.3389\/fnagi.2023.1091919","volume":"15","author":"J Ren","year":"2023","unstructured":"Ren J, Zhou G, Wang Y, Zhang R, Guo Z, Zhou H, et al. Association of GBA genotype with motor and cognitive decline in Chinese Parkinson\u2019s disease patients. Front Aging Neurosci. 2023;15:1091919.","journal-title":"Front Aging Neurosci"},{"key":"437_CR83","doi-asserted-by":"publisher","first-page":"527","DOI":"10.3389\/fneur.2020.00527","volume":"11","author":"DA Olszewska","year":"2020","unstructured":"Olszewska DA, McCarthy A, Soto-Beasley AI, Walton RL, Magennis B, McLaughlin RL, et al. Association between glucocerebrosidase mutations and Parkinson\u2019s disease in Ireland. Front Neurol. 2020;11:527.","journal-title":"Front Neurol"},{"issue":"3","key":"437_CR84","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1212\/WNL.0b013e318225ab77","volume":"77","author":"K Brockmann","year":"2011","unstructured":"Brockmann K, Srulijes K, Hauser AK, Schulte C, Csoti I, Gasser T, et al. GBA-associated PD presents with nonmotor characteristics. Neurology. 2011;77(3):276\u201380.","journal-title":"Neurology"},{"issue":"12","key":"437_CR85","doi-asserted-by":"publisher","first-page":"e0167749","DOI":"10.1371\/journal.pone.0167749","volume":"11","author":"S Jesus","year":"2016","unstructured":"Jesus S, Huertas I, Bernal-Bernal I, Bonilla-Toribio M, Caceres-Redondo MT, Vargas-Gonzalez L, et al. GBA variants influence motor and non-motor features of Parkinson\u2019s disease. PLoS ONE. 2016;11(12):e0167749.","journal-title":"PLoS ONE"},{"key":"437_CR86","doi-asserted-by":"publisher","first-page":"e14387","DOI":"10.1111\/cns.14387","volume":"30","author":"J Ren","year":"2023","unstructured":"Ren J, Zhan X, Zhou H, Guo Z, Xing Y, Yin H, et al. Comparing the effects of GBA variants and onset age on clinical features and progression in Parkinson\u2019s disease. CNS Neurosci Ther. 2023;30:e14387.","journal-title":"CNS Neurosci Ther"},{"issue":"3","key":"437_CR87","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1002\/mds.26071","volume":"30","author":"K Brockmann","year":"2015","unstructured":"Brockmann K, Srulijes K, Pflederer S, Hauser AK, Schulte C, Maetzler W, et al. GBA-associated Parkinson\u2019s disease: reduced survival and more rapid progression in a prospective longitudinal study. Mov Disord. 2015;30(3):407\u201311.","journal-title":"Mov Disord"},{"issue":"5","key":"437_CR88","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1002\/ana.24781","volume":"80","author":"G Liu","year":"2016","unstructured":"Liu G, Boot B, Locascio JJ, Jansen IE, Winder-Rhodes S, Eberly S, et al. Specifically neuropathic Gaucher\u2019s mutations accelerate cognitive decline in Parkinson\u2019s. Ann Neurol. 2016;80(5):674\u201385.","journal-title":"Ann Neurol"},{"issue":"3","key":"437_CR89","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1002\/mds.24045","volume":"27","author":"N Seto-Salvia","year":"2012","unstructured":"Seto-Salvia N, Pagonabarraga J, Houlden H, Pascual-Sedano B, Dols-Icardo O, Tucci A, et al. Glucocerebrosidase mutations confer a greater risk of dementia during Parkinson\u2019s disease course. Mov Disord. 2012;27(3):393\u20139.","journal-title":"Mov Disord"},{"issue":"1","key":"437_CR90","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1002\/mds.26359","volume":"31","author":"IF Mata","year":"2016","unstructured":"Mata IF, Leverenz JB, Weintraub D, Trojanowski JQ, Chen-Plotkin A, Van Deerlin VM, et al. GBA variants are associated with a distinct pattern of cognitive deficits in Parkinson\u2019s disease. Mov Disord. 2016;31(1):95\u2013102.","journal-title":"Mov Disord"},{"issue":"6","key":"437_CR91","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1001\/jamaneurol.2013.1925","volume":"70","author":"MA Nalls","year":"2013","unstructured":"Nalls MA, Duran R, Lopez G, Kurzawa-Akanbi M, McKeith IG, Chinnery PF, et al. A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies. JAMA Neurol. 2013;70(6):727\u201335.","journal-title":"JAMA Neurol"},{"issue":"12","key":"437_CR92","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1001\/jamaneurol.2016.1593","volume":"73","author":"T Shiner","year":"2016","unstructured":"Shiner T, Mirelman A, Gana Weisz M, Bar-Shira A, Ash E, Cialic R, et al. High frequency of GBA gene mutations in dementia with Lewy bodies among Ashkenazi Jews. JAMA Neurol. 2016;73(12):1448\u201353.","journal-title":"JAMA Neurol"},{"issue":"4","key":"437_CR93","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.5845","volume":"4","author":"RA Ortega","year":"2021","unstructured":"Ortega RA, Wang C, Raymond D, Bryant N, Scherzer CR, Thaler A, et al. Association of dual LRRK2 G2019S and GBA variations with Parkinson disease progression. JAMA Netw Open. 2021;4(4): e215845.","journal-title":"JAMA Netw Open"},{"issue":"7","key":"437_CR94","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1002\/mds.28066","volume":"35","author":"N Omer","year":"2020","unstructured":"Omer N, Giladi N, Gurevich T, Bar-Shira A, Gana-Weisz M, Goldstein O, et al. A Possible modifying effect of the G2019S mutation in the LRRK2 gene on GBA Parkinson\u2019s disease. Mov Disord. 2020;35(7):1249\u201353.","journal-title":"Mov Disord"},{"issue":"1","key":"437_CR95","doi-asserted-by":"publisher","first-page":"5570","DOI":"10.1038\/s41467-019-13413-w","volume":"10","author":"D Ysselstein","year":"2019","unstructured":"Ysselstein D, Nguyen M, Young TJ, Severino A, Schwake M, Merchant K, et al. LRRK2 kinase activity regulates lysosomal glucocerebrosidase in neurons derived from Parkinson\u2019s disease patients. Nat Commun. 2019;10(1):5570.","journal-title":"Nat Commun"},{"issue":"1","key":"437_CR96","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s40035-022-00281-6","volume":"11","author":"SY Pang","year":"2022","unstructured":"Pang SY, Lo RCN, Ho PW, Liu HF, Chang EES, Leung CT, et al. LRRK2, GBA and their interaction in the regulation of autophagy: implications on therapeutics in Parkinson\u2019s disease. Transl Neurodegener. 2022;11(1):5.","journal-title":"Transl Neurodegener"},{"issue":"5","key":"437_CR97","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1002\/mds.28932","volume":"37","author":"AA Szwedo","year":"2022","unstructured":"Szwedo AA, Dalen I, Pedersen KF, Camacho M, Backstrom D, Forsgren L, et al. GBA and APOE impact cognitive decline in Parkinson\u2019s disease: a 10-year population-based study. Mov Disord. 2022;37(5):1016\u201327.","journal-title":"Mov Disord"},{"key":"437_CR98","doi-asserted-by":"crossref","unstructured":"Saha O, Melo de Farias AR, Pelletier A, Siedlecki-Wullich D, Landeira BS, Gadaut J, et al. The Alzheimer's disease risk gene BIN1 regulates activity-dependent gene expression in human-induced glutamatergic neurons. Mol Psychiatry. 2024.","DOI":"10.1038\/s41380-024-02502-y"},{"issue":"4","key":"437_CR99","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1093\/brain\/awac318","volume":"146","author":"M Ponnusamy","year":"2023","unstructured":"Ponnusamy M, Wang S, Yuksel M, Hansen MT, Blazier DM, McMillan JD, et al. Loss of forebrain BIN1 attenuates hippocampal pathology and neuroinflammation in a tauopathy model. Brain. 2023;146(4):1561\u201379.","journal-title":"Brain"},{"issue":"1","key":"437_CR100","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s13024-022-00535-x","volume":"17","author":"A Sudwarts","year":"2022","unstructured":"Sudwarts A, Ramesha S, Gao T, Ponnusamy M, Wang S, Hansen M, et al. BIN1 is a key regulator of proinflammatory and neurodegeneration-related activation in microglia. Mol Neurodegener. 2022;17(1):33.","journal-title":"Mol Neurodegener"},{"issue":"11","key":"437_CR101","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1007\/s00415-015-7868-3","volume":"262","author":"Z Gan-Or","year":"2015","unstructured":"Gan-Or Z, Amshalom I, Bar-Shira A, Gana-Weisz M, Mirelman A, Marder K, et al. The Alzheimer disease BIN1 locus as a modifier of GBA-associated Parkinson disease. J Neurol. 2015;262(11):2443\u20137.","journal-title":"J Neurol"},{"issue":"10","key":"437_CR102","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1001\/jamaneurol.2016.2245","volume":"73","author":"MY Davis","year":"2016","unstructured":"Davis MY, Johnson CO, Leverenz JB, Weintraub D, Trojanowski JQ, Chen-Plotkin A, et al. Association of GBA mutations and the E326K polymorphism with motor and cognitive progression in Parkinson disease. JAMA Neurol. 2016;73(10):1217\u201324.","journal-title":"JAMA Neurol"},{"issue":"1","key":"437_CR103","doi-asserted-by":"publisher","first-page":"269","DOI":"10.3233\/JAD-210365","volume":"83","author":"SJ van der Lee","year":"2021","unstructured":"van der Lee SJ, van Steenoven I, van de Beek M, Tesi N, Jansen IE, van Schoor NM, et al. Genetics contributes to concomitant pathology and clinical presentation in dementia with Lewy bodies. J Alzheimers Dis. 2021;83(1):269\u201379.","journal-title":"J Alzheimers Dis"},{"issue":"4","key":"437_CR104","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1111\/ene.15230","volume":"29","author":"J Ren","year":"2022","unstructured":"Ren J, Zhang R, Pan C, Xu J, Sun H, Hua P, et al. Prevalence and genotype-phenotype correlations of GBA-related Parkinson disease in a large Chinese cohort. Eur J Neurol. 2022;29(4):1017\u201324.","journal-title":"Eur J Neurol"},{"issue":"1","key":"437_CR105","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/S1474-4422(19)30319-9","volume":"19","author":"T Simuni","year":"2020","unstructured":"Simuni T, Uribe L, Cho HR, Caspell-Garcia C, Coffey CS, Siderowf A, et al. Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson\u2019s Progression Markers Initiative (PPMI): a cross-sectional study. Lancet Neurol. 2020;19(1):71\u201380.","journal-title":"Lancet Neurol"},{"issue":"12","key":"437_CR106","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1002\/humu.23611","volume":"39","author":"BA Davidson","year":"2018","unstructured":"Davidson BA, Hassan S, Garcia EJ, Tayebi N, Sidransky E. Exploring genetic modifiers of Gaucher disease: the next horizon. Hum Mutat. 2018;39(12):1739\u201351.","journal-title":"Hum Mutat"},{"issue":"11","key":"437_CR107","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1093\/hmg\/ddad025","volume":"32","author":"M Kumar","year":"2023","unstructured":"Kumar M, Srikanth MP, Deleidi M, Hallett PJ, Isacson O, Feldman RA. Acid ceramidase involved in pathogenic cascade leading to accumulation of alpha-synuclein in iPSC model of GBA1-associated Parkinson\u2019s disease. Hum Mol Genet. 2023;32(11):1888\u2013900.","journal-title":"Hum Mol Genet"},{"key":"437_CR108","doi-asserted-by":"publisher","first-page":"104545","DOI":"10.1016\/j.nbd.2019.104545","volume":"132","author":"LF Burbulla","year":"2019","unstructured":"Burbulla LF, Krainc D. The role of dopamine in the pathogenesis of GBA1-linked Parkinson\u2019s disease. Neurobiol Dis. 2019;132:104545.","journal-title":"Neurobiol Dis"},{"key":"437_CR109","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s40035-015-0042-0","volume":"4","author":"Q Wang","year":"2015","unstructured":"Wang Q, Liu Y, Zhou J. Neuroinflammation in Parkinson\u2019s disease and its potential as therapeutic target. Transl Neurodegener. 2015;4:19.","journal-title":"Transl Neurodegener"},{"key":"437_CR110","doi-asserted-by":"publisher","first-page":"105612","DOI":"10.1016\/j.nbd.2022.105612","volume":"163","author":"A Polissidis","year":"2022","unstructured":"Polissidis A, Koronaiou E, Nikolopoulou G, Viel C, Nikatou M, Bogiongko M, et al. A double-hit in vivo model of GBA viral microRNA-mediated downregulation and human alpha-synuclein overexpression demonstrates nigrostriatal degeneration. Neurobiol Dis. 2022;163:105612.","journal-title":"Neurobiol Dis"},{"issue":"11","key":"437_CR111","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1093\/hmg\/ddz005","volume":"28","author":"G Maor","year":"2019","unstructured":"Maor G, Rapaport D, Horowitz M. The effect of mutant GBA1 on accumulation and aggregation of alpha-synuclein. Hum Mol Genet. 2019;28(11):1768\u201381.","journal-title":"Hum Mol Genet"},{"issue":"5","key":"437_CR112","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1002\/mds.28396","volume":"36","author":"P Garcia-Sanz","year":"2021","unstructured":"Garcia-Sanz P, Aerts JMFG, Moratalla R. The role of cholesterol in alpha-synuclein and Lewy body pathology in GBA1 Parkinson\u2019s disease. Mov Disord. 2021;36(5):1070\u201385.","journal-title":"Mov Disord"},{"issue":"7","key":"437_CR113","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.3390\/cells9071687","volume":"9","author":"M Pajares","year":"2020","unstructured":"Pajares M, Rojo AI, Manda G, Bosca L, Cuadrado A. Inflammation in Parkinson\u2019s disease: mechanisms and therapeutic implications. Cells. 2020;9(7):1687.","journal-title":"Cells"},{"issue":"5","key":"437_CR114","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/j.neuron.2019.12.004","volume":"105","author":"MX Henderson","year":"2020","unstructured":"Henderson MX, Sedor S, McGeary I, Cornblath EJ, Peng C, Riddle DM, et al. Glucocerebrosidase activity modulates neuronal susceptibility to pathological alpha-synuclein insult. Neuron. 2020;105(5):822-836 e7.","journal-title":"Neuron"},{"issue":"2","key":"437_CR115","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nm.4269","volume":"23","author":"YC Wong","year":"2017","unstructured":"Wong YC, Krainc D. alpha-synuclein toxicity in neurodegeneration: mechanism and therapeutic strategies. Nat Med. 2017;23(2):1\u201313.","journal-title":"Nat Med"},{"issue":"6357","key":"437_CR116","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1126\/science.aam9080","volume":"357","author":"LF Burbulla","year":"2017","unstructured":"Burbulla LF, Song P, Mazzulli JR, Zampese E, Wong YC, Jeon S, et al. Dopamine oxidation mediates mitochondrial and lysosomal dysfunction in Parkinson\u2019s disease. Science. 2017;357(6357):1255\u201361.","journal-title":"Science"},{"issue":"21","key":"437_CR117","doi-asserted-by":"publisher","first-page":"5576","DOI":"10.1073\/pnas.1717590115","volume":"115","author":"M Nguyen","year":"2018","unstructured":"Nguyen M, Krainc D. LRRK2 phosphorylation of auxilin mediates synaptic defects in dopaminergic neurons from patients with Parkinson\u2019s disease. Proc Natl Acad Sci U S A. 2018;115(21):5576\u201381.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"437_CR118","doi-asserted-by":"publisher","first-page":"168023","DOI":"10.1016\/j.jmb.2023.168023","volume":"435","author":"D Chatterjee","year":"2023","unstructured":"Chatterjee D, Krainc D. Mechanisms of glucocerebrosidase dysfunction in Parkinson\u2019s disease. J Mol Biol. 2023;435(12):168023.","journal-title":"J Mol Biol"},{"issue":"1","key":"437_CR119","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/s41531-023-00616-8","volume":"9","author":"I Rosety","year":"2023","unstructured":"Rosety I, Zagare A, Saraiva C, Nickels S, Antony P, Almeida C, et al. Impaired neuron differentiation in GBA-associated Parkinson\u2019s disease is linked to cell cycle defects in organoids. NPJ Parkinsons Dis. 2023;9(1):166.","journal-title":"NPJ Parkinsons Dis"},{"issue":"1","key":"437_CR120","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s40035-020-00226-x","volume":"10","author":"T Behl","year":"2021","unstructured":"Behl T, Kaur G, Fratila O, Buhas C, Judea-Pusta CT, Negrut N, et al. Cross-talks among GBA mutations, glucocerebrosidase, and alpha-synuclein in GBA-associated Parkinson\u2019s disease and their targeted therapeutic approaches: a comprehensive review. Transl Neurodegener. 2021;10(1):4.","journal-title":"Transl Neurodegener"},{"issue":"1","key":"437_CR121","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.cell.2011.06.001","volume":"146","author":"JR Mazzulli","year":"2011","unstructured":"Mazzulli JR, Xu YH, Sun Y, Knight AL, McLean PJ, Caldwell GA, et al. Gaucher disease glucocerebrosidase and alpha-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell. 2011;146(1):37\u201352.","journal-title":"Cell"},{"issue":"4","key":"437_CR122","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.neuron.2017.01.018","volume":"93","author":"E Aflaki","year":"2017","unstructured":"Aflaki E, Westbroek W, Sidransky E. The complicated relationship between Gaucher disease and Parkinsonism: insights from a rare disease. Neuron. 2017;93(4):737\u201346.","journal-title":"Neuron"},{"issue":"Pt 3","key":"437_CR123","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1093\/brain\/awt367","volume":"137","author":"KE Murphy","year":"2014","unstructured":"Murphy KE, Gysbers AM, Abbott SK, Tayebi N, Kim WS, Sidransky E, et al. Reduced glucocerebrosidase is associated with increased alpha-synuclein in sporadic Parkinson\u2019s disease. Brain. 2014;137(Pt 3):834\u201348.","journal-title":"Brain"},{"issue":"41","key":"437_CR124","doi-asserted-by":"publisher","first-page":"7161","DOI":"10.1021\/bi401191v","volume":"52","author":"TL Yap","year":"2013","unstructured":"Yap TL, Gruschus JM, Velayati A, Sidransky E, Lee JC. Saposin C protects glucocerebrosidase against alpha-synuclein inhibition. Biochemistry. 2013;52(41):7161\u20133.","journal-title":"Biochemistry"},{"issue":"9","key":"437_CR125","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1016\/j.neurobiolaging.2015.06.004","volume":"36","author":"G Liu","year":"2015","unstructured":"Liu G, Chen M, Mi N, Yang W, Li X, Wang P, et al. Increased oligomerization and phosphorylation of alpha-synuclein are associated with decreased activity of glucocerebrosidase and protein phosphatase 2A in aging monkey brains. Neurobiol Aging. 2015;36(9):2649\u201359.","journal-title":"Neurobiol Aging"},{"issue":"1","key":"437_CR126","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s40035-020-00218-x","volume":"9","author":"CU von Linstow","year":"2020","unstructured":"von Linstow CU, Gan-Or Z, Brundin P. Precision medicine in Parkinson\u2019s disease patients with LRRK2 and GBA risk variants\u2014let\u2019s get even more personal. Transl Neurodegener. 2020;9(1):39.","journal-title":"Transl Neurodegener"},{"key":"437_CR127","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.neulet.2014.09.041","volume":"583","author":"SN Pchelina","year":"2014","unstructured":"Pchelina SN, Nuzhnyi EP, Emelyanov AK, Boukina TM, Usenko TS, Nikolaev MA, et al. Increased plasma oligomeric alpha-synuclein in patients with lysosomal storage diseases. Neurosci Lett. 2014;583:188\u201393.","journal-title":"Neurosci Lett"},{"key":"437_CR128","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.nbd.2018.09.015","volume":"121","author":"AL Gundner","year":"2019","unstructured":"Gundner AL, Duran-Pacheco G, Zimmermann S, Ruf I, Moors T, Baumann K, et al. Path mediation analysis reveals GBA impacts Lewy body disease status by increasing alpha-synuclein levels. Neurobiol Dis. 2019;121:205\u201313.","journal-title":"Neurobiol Dis"},{"key":"437_CR129","doi-asserted-by":"publisher","first-page":"104856","DOI":"10.1016\/j.neubiorev.2022.104856","volume":"141","author":"S Gaubert","year":"2022","unstructured":"Gaubert S, Hourregue C, Mouton-Liger F, Millot P, Franco M, Amar-Bouaziz E, et al. Exploring the link between GBA1 mutations and Dementia with Lewy bodies, a mini-review. Neurosci Biobehav Rev. 2022;141:104856.","journal-title":"Neurosci Biobehav Rev"},{"issue":"5","key":"437_CR130","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/s00401-010-0741-7","volume":"120","author":"O Goker-Alpan","year":"2010","unstructured":"Goker-Alpan O, Stubblefield BK, Giasson BI, Sidransky E. Glucocerebrosidase is present in alpha-synuclein inclusions in Lewy body disorders. Acta Neuropathol. 2010;120(5):641\u20139.","journal-title":"Acta Neuropathol"},{"issue":"1","key":"437_CR131","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41531-023-00517-w","volume":"9","author":"CEG Leyns","year":"2023","unstructured":"Leyns CEG, Prigent A, Beezhold B, Yao L, Hatcher NG, Tao P, et al. Glucocerebrosidase activity and lipid levels are related to protein pathologies in Parkinson\u2019s disease. NPJ Parkinsons Dis. 2023;9(1):74.","journal-title":"NPJ Parkinsons Dis"},{"key":"437_CR132","doi-asserted-by":"publisher","first-page":"330","DOI":"10.3389\/fnins.2019.00330","volume":"13","author":"N Plotegher","year":"2019","unstructured":"Plotegher N, Bubacco L, Greggio E, Civiero L. Ceramides in Parkinson\u2019s disease: from recent evidence to new hypotheses. Front Neurosci. 2019;13:330.","journal-title":"Front Neurosci"},{"issue":"1","key":"437_CR133","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/s41598-017-18405-8","volume":"8","author":"G Batta","year":"2018","unstructured":"Batta G, Soltesz L, Kovacs T, Bozo T, Meszar Z, Kellermayer M, et al. Alterations in the properties of the cell membrane due to glycosphingolipid accumulation in a model of Gaucher disease. Sci Rep. 2018;8(1):157.","journal-title":"Sci Rep"},{"issue":"5","key":"437_CR134","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1002\/mds.28472","volume":"36","author":"S Lerche","year":"2021","unstructured":"Lerche S, Schulte C, Wurster I, Machetanz G, Roeben B, Zimmermann M, et al. The Mutation matters: CSF profiles of GCase, sphingolipids, alpha-synuclein in PD(GBA). Mov Disord. 2021;36(5):1216\u201328.","journal-title":"Mov Disord"},{"issue":"10","key":"437_CR135","doi-asserted-by":"publisher","first-page":"6387","DOI":"10.1021\/cr2002917","volume":"111","author":"AH Merrill Jr","year":"2011","unstructured":"Merrill AH Jr. Sphingolipid and glycosphingolipid metabolic pathways in the era of sphingolipidomics. Chem Rev. 2011;111(10):6387\u2013422.","journal-title":"Chem Rev"},{"issue":"40","key":"437_CR136","doi-asserted-by":"publisher","first-page":"9617","DOI":"10.1523\/JNEUROSCI.1525-17.2017","volume":"37","author":"YV Taguchi","year":"2017","unstructured":"Taguchi YV, Liu J, Ruan J, Pacheco J, Zhang X, Abbasi J, et al. Glucosylsphingosine promotes alpha-synuclein pathology in mutant GBA-associated Parkinson\u2019s disease. J Neurosci. 2017;37(40):9617\u201331.","journal-title":"J Neurosci"},{"issue":"6","key":"437_CR137","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1002\/1873-3468.12104","volume":"590","author":"MJ Ferraz","year":"2016","unstructured":"Ferraz MJ, Marques AR, Appelman MD, Verhoek M, Strijland A, Mirzaian M, et al. Lysosomal glycosphingolipid catabolism by acid ceramidase: formation of glycosphingoid bases during deficiency of glycosidases. FEBS Lett. 2016;590(6):716\u201325.","journal-title":"FEBS Lett"},{"issue":"10","key":"437_CR138","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1002\/mds.29204","volume":"37","author":"P Lansbury","year":"2022","unstructured":"Lansbury P. The sphingolipids clearly play a role in Parkinson\u2019s disease, but nature has made it complicated. Mov Disord. 2022;37(10):1985\u20139.","journal-title":"Mov Disord"},{"issue":"5","key":"437_CR139","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1002\/mds.29360","volume":"38","author":"JM den Heijer","year":"2023","unstructured":"den Heijer JM, Cullen VC, Pereira DR, Yavuz Y, de Kam ML, Grievink HW, et al. A biomarker study in patients with GBA1-Parkinson\u2019s disease and healthy controls. Mov Disord. 2023;38(5):783\u201395.","journal-title":"Mov Disord"},{"issue":"26","key":"437_CR140","doi-asserted-by":"publisher","first-page":"7065","DOI":"10.1073\/pnas.1601899113","volume":"113","author":"C Galvagnion","year":"2016","unstructured":"Galvagnion C, Brown JW, Ouberai MM, Flagmeier P, Vendruscolo M, Buell AK, et al. Chemical properties of lipids strongly affect the kinetics of the membrane-induced aggregation of alpha-synuclein. Proc Natl Acad Sci U S A. 2016;113(26):7065\u201370.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"28","key":"437_CR141","doi-asserted-by":"publisher","first-page":"11195","DOI":"10.1074\/jbc.RA118.002780","volume":"293","author":"EI O'Leary","year":"2018","unstructured":"O\u2019Leary EI, Jiang Z, Strub MP, Lee JC. Effects of phosphatidylcholine membrane fluidity on the conformation and aggregation of N-terminally acetylated alpha-synuclein. J Biol Chem. 2018;293(28):11195\u2013205.","journal-title":"J Biol Chem"},{"issue":"50","key":"437_CR142","doi-asserted-by":"publisher","first-page":"e2108489118","DOI":"10.1073\/pnas.2108489118","volume":"118","author":"K Fredriksen","year":"2021","unstructured":"Fredriksen K, Aivazidis S, Sharma K, Burbidge KJ, Pitcairn C, Zunke F, et al. Pathological alpha-syn aggregation is mediated by glycosphingolipid chain length and the physiological state of alpha-syn in vivo. Proc Natl Acad Sci U S A. 2021;118(50):e2108489118.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"437_CR143","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.neuron.2017.12.012","volume":"97","author":"F Zunke","year":"2018","unstructured":"Zunke F, Moise AC, Belur NR, Gelyana E, Stojkovska I, Dzaferbegovic H, et al. Reversible conformational conversion of alpha-synuclein into toxic assemblies by glucosylceramide. Neuron. 2018;97(1):92-107 e10.","journal-title":"Neuron"},{"issue":"2","key":"437_CR144","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1074\/jbc.M114.610584","volume":"290","author":"TL Yap","year":"2015","unstructured":"Yap TL, Jiang Z, Heinrich F, Gruschus JM, Pfefferkorn CM, Barros M, et al. Structural features of membrane-bound glucocerebrosidase and alpha-synuclein probed by neutron reflectometry and fluorescence spectroscopy. J Biol Chem. 2015;290(2):744\u201354.","journal-title":"J Biol Chem"},{"issue":"1","key":"437_CR145","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.ymgme.2012.11.010","volume":"108","author":"TL Yap","year":"2013","unstructured":"Yap TL, Velayati A, Sidransky E, Lee JC. Membrane-bound alpha-synuclein interacts with glucocerebrosidase and inhibits enzyme activity. Mol Genet Metab. 2013;108(1):56\u201364.","journal-title":"Mol Genet Metab"},{"key":"437_CR146","doi-asserted-by":"publisher","first-page":"105507","DOI":"10.1016\/j.nbd.2021.105507","volume":"159","author":"M Cosden","year":"2021","unstructured":"Cosden M, Jinn S, Yao L, Gretzula CA, Kandebo M, Toolan D, et al. A novel glucosylceramide synthase inhibitor attenuates alpha synuclein pathology and lysosomal dysfunction in preclinical models of synucleinopathy. Neurobiol Dis. 2021;159:105507.","journal-title":"Neurobiol Dis"},{"key":"437_CR147","doi-asserted-by":"publisher","first-page":"100972","DOI":"10.1016\/j.mam.2021.100972","volume":"82","author":"BN Lizama","year":"2021","unstructured":"Lizama BN, Chu CT. Neuronal autophagy and mitophagy in Parkinson\u2019s disease. Mol Aspects Med. 2021;82:100972.","journal-title":"Mol Aspects Med"},{"issue":"5","key":"437_CR148","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1002\/mds.27994","volume":"35","author":"A Sanyal","year":"2020","unstructured":"Sanyal A, DeAndrade MP, Novis HS, Lin S, Chang J, Lengacher N, et al. Lysosome and inflammatory defects in GBA1-mutant astrocytes are normalized by LRRK2 inhibition. Mov Disord. 2020;35(5):760\u201373.","journal-title":"Mov Disord"},{"issue":"16","key":"437_CR149","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1056\/NEJMra2022774","volume":"383","author":"N Mizushima","year":"2020","unstructured":"Mizushima N, Levine B. Autophagy in human diseases. N Engl J Med. 2020;383(16):1564\u201376.","journal-title":"N Engl J Med"},{"issue":"19","key":"437_CR150","doi-asserted-by":"publisher","first-page":"e108863","DOI":"10.15252\/embj.2021108863","volume":"40","author":"DJ Klionsky","year":"2021","unstructured":"Klionsky DJ, Petroni G, Amaravadi RK, Baehrecke EH, Ballabio A, Boya P, et al. Autophagy in major human diseases. EMBO J. 2021;40(19):e108863.","journal-title":"EMBO J"},{"issue":"10","key":"437_CR151","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.3390\/biom13101435","volume":"13","author":"L Nechushtai","year":"2023","unstructured":"Nechushtai L, Frenkel D, Pinkas-Kramarski R. Autophagy in Parkinson\u2019s disease. Biomolecules. 2023;13(10):1435.","journal-title":"Biomolecules"},{"issue":"5688","key":"437_CR152","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1126\/science.1101738","volume":"305","author":"AM Cuervo","year":"2004","unstructured":"Cuervo AM, Stefanis L, Fredenburg R, Lansbury PT, Sulzer D. Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science. 2004;305(5688):1292\u20135.","journal-title":"Science"},{"issue":"4","key":"437_CR153","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1097\/00001756-200303240-00004","volume":"14","author":"K Suzuki","year":"2003","unstructured":"Suzuki K, Iseki E, Katsuse O, Yamaguchi A, Katsuyama K, Aoki I, et al. Neuronal accumulation of alpha- and beta-synucleins in the brain of a GM2 gangliosidosis mouse model. NeuroReport. 2003;14(4):551\u20134.","journal-title":"NeuroReport"},{"issue":"4","key":"437_CR154","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1080\/15548627.2018.1427396","volume":"14","author":"P Garcia-Sanz","year":"2018","unstructured":"Garcia-Sanz P, Orgaz L, Fuentes JM, Vicario C, Moratalla R. Cholesterol and multilamellar bodies: Lysosomal dysfunction in GBA-Parkinson disease. Autophagy. 2018;14(4):717\u20138.","journal-title":"Autophagy"},{"issue":"12","key":"437_CR155","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1001\/archneurol.2010.198","volume":"67","author":"L Alvarez-Erviti","year":"2010","unstructured":"Alvarez-Erviti L, Rodriguez-Oroz MC, Cooper JM, Caballero C, Ferrer I, Obeso JA, et al. Chaperone-mediated autophagy markers in Parkinson disease brains. Arch Neurol. 2010;67(12):1464\u201372.","journal-title":"Arch Neurol"},{"issue":"6","key":"437_CR156","doi-asserted-by":"publisher","first-page":"eabm6393","DOI":"10.1126\/sciadv.abm6393","volume":"8","author":"SH Kuo","year":"2022","unstructured":"Kuo SH, Tasset I, Cheng MM, Diaz A, Pan MK, Lieberman OJ, et al. Mutant glucocerebrosidase impairs alpha-synuclein degradation by blockade of chaperone-mediated autophagy. Sci Adv. 2022;8(6):eabm6393.","journal-title":"Sci Adv"},{"issue":"6","key":"437_CR157","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1002\/ana.22400","volume":"69","author":"V Cullen","year":"2011","unstructured":"Cullen V, Sardi SP, Ng J, Xu YH, Sun Y, Tomlinson JJ, et al. Acid beta-glucosidase mutants linked to Gaucher disease, Parkinson disease, and Lewy body dementia alter alpha-synuclein processing. Ann Neurol. 2011;69(6):940\u201353.","journal-title":"Ann Neurol"},{"issue":"43","key":"437_CR158","doi-asserted-by":"publisher","first-page":"13578","DOI":"10.1523\/JNEUROSCI.4390-09.2009","volume":"29","author":"B Spencer","year":"2009","unstructured":"Spencer B, Potkar R, Trejo M, Rockenstein E, Patrick C, Gindi R, et al. Beclin 1 gene transfer activates autophagy and ameliorates the neurodegenerative pathology in alpha-synuclein models of Parkinson\u2019s and Lewy body diseases. J Neurosci. 2009;29(43):13578\u201388.","journal-title":"J Neurosci"},{"issue":"379","key":"437_CR159","first-page":"20220381","volume":"2024","author":"A Hull","year":"1899","unstructured":"Hull A, Atilano ML, Gergi L, Kinghorn KJ. Lysosomal storage, impaired autophagy and innate immunity in Gaucher and Parkinson\u2019s diseases: insights for drug discovery. Philos Trans R Soc Lond B Biol Sci. 1899;2024(379):20220381.","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"issue":"3","key":"437_CR160","doi-asserted-by":"publisher","first-page":"380","DOI":"10.4103\/1673-5374.202934","volume":"12","author":"KJ Kinghorn","year":"2017","unstructured":"Kinghorn KJ, Asghari AM, Castillo-Quan JI. The emerging role of autophagic-lysosomal dysfunction in Gaucher disease and Parkinson\u2019s disease. Neural Regen Res. 2017;12(3):380\u20134.","journal-title":"Neural Regen Res"},{"issue":"15","key":"437_CR161","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.3390\/cells11152343","volume":"11","author":"G Lunghi","year":"2022","unstructured":"Lunghi G, Carsana EV, Loberto N, Cioccarelli L, Prioni S, Mauri L, et al. beta-Glucocerebrosidase deficiency activates an aberrant lysosome-plasma membrane axis responsible for the onset of neurodegeneration. Cells. 2022;11(15):2343.","journal-title":"Cells"},{"issue":"8","key":"437_CR162","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1002\/mds.26278","volume":"30","author":"ME Gegg","year":"2015","unstructured":"Gegg ME, Sweet L, Wang BH, Shihabuddin LS, Sardi SP, Schapira AH. No evidence for substrate accumulation in Parkinson brains with GBA mutations. Mov Disord. 2015;30(8):1085\u20139.","journal-title":"Mov Disord"},{"issue":"6","key":"437_CR163","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1002\/mds.28987","volume":"37","author":"L Straniero","year":"2022","unstructured":"Straniero L, Rimoldi V, Monfrini E, Bonvegna S, Melistaccio G, Lake J, et al. Role of lysosomal gene variants in modulating GBA-associated Parkinson\u2019s disease risk. Mov Disord. 2022;37(6):1202\u201310.","journal-title":"Mov Disord"},{"issue":"12","key":"437_CR164","doi-asserted-by":"publisher","first-page":"167932","DOI":"10.1016\/j.jmb.2022.167932","volume":"435","author":"R Machtel","year":"2023","unstructured":"Machtel R, Boros FA, Dobert JP, Arnold P, Zunke F. From lysosomal storage disorders to Parkinson\u2019s disease\u2014challenges and opportunities. J Mol Biol. 2023;435(12):167932.","journal-title":"J Mol Biol"},{"issue":"9","key":"437_CR165","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/S1474-4422(19)30195-4","volume":"18","author":"SY Lim","year":"2019","unstructured":"Lim SY, Tan AH, Ahmad-Annuar A, Klein C, Tan LCS, Rosales RL, et al. Parkinson\u2019s disease in the Western Pacific region. Lancet Neurol. 2019;18(9):865\u201379.","journal-title":"Lancet Neurol"},{"key":"437_CR166","doi-asserted-by":"publisher","first-page":"681369","DOI":"10.3389\/fneur.2021.681369","volume":"12","author":"T Abe","year":"2021","unstructured":"Abe T, Kuwahara T. Targeting of lysosomal pathway genes for Parkinson\u2019s disease modification: insights from cellular and animal models. Front Neurol. 2021;12:681369.","journal-title":"Front Neurol"},{"issue":"4","key":"437_CR167","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1001\/jamaneurol.2020.5257","volume":"78","author":"DA Kia","year":"2021","unstructured":"Kia DA, Zhang D, Guelfi S, Manzoni C, Hubbard L, Reynolds RH, et al. Identification of candidate Parkinson disease genes by integrating genome-wide association study, expression, and epigenetic data sets. JAMA Neurol. 2021;78(4):464\u201372.","journal-title":"JAMA Neurol"},{"key":"437_CR168","doi-asserted-by":"publisher","first-page":"749109","DOI":"10.3389\/fnagi.2021.749109","volume":"13","author":"YW Zhao","year":"2021","unstructured":"Zhao YW, Pan HX, Liu Z, Wang Y, Zeng Q, Fang ZH, et al. The association between lysosomal storage disorder genes and Parkinson\u2019s disease: a large cohort study in Chinese mainland population. Front Aging Neurosci. 2021;13:749109.","journal-title":"Front Aging Neurosci"},{"issue":"10","key":"437_CR169","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1038\/ng.3955","volume":"49","author":"D Chang","year":"2017","unstructured":"Chang D, Nalls MA, Hallgrimsdottir IB, Hunkapiller J, van der Brug M, Cai F, et al. A meta-analysis of genome-wide association studies identifies 17 new Parkinson\u2019s disease risk loci. Nat Genet. 2017;49(10):1511\u20136.","journal-title":"Nat Genet"},{"issue":"1","key":"437_CR170","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1002\/ana.25629","volume":"87","author":"L Krohn","year":"2020","unstructured":"Krohn L, Ozturk TN, Vanderperre B, Ouled Amar Bencheikh B, Ruskey JA, Laurent SB, et al. Genetic, structural, and functional evidence link TMEM175 to synucleinopathies. Ann Neurol. 2020;87(1):139\u201353.","journal-title":"Ann Neurol"},{"issue":"7","key":"437_CR171","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1002\/mds.28037","volume":"35","author":"F Hopfner","year":"2020","unstructured":"Hopfner F, Mueller SH, Szymczak S, Junge O, Tittmann L, May S, et al. Rare variants in specific lysosomal genes are associated with Parkinson\u2019s disease. Mov Disord. 2020;35(7):1245\u20138.","journal-title":"Mov Disord"},{"issue":"10","key":"437_CR172","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.molmed.2020.07.004","volume":"26","author":"N Tayebi","year":"2020","unstructured":"Tayebi N, Lopez G, Do J, Sidransky E, Pro-cathepsin D. Prosaposin, and progranulin: lysosomal networks in Parkinsonism. Trends Mol Med. 2020;26(10):913\u201323.","journal-title":"Trends Mol Med"},{"issue":"43","key":"437_CR173","doi-asserted-by":"publisher","first-page":"15573","DOI":"10.1073\/pnas.1405700111","volume":"111","author":"M Rothaug","year":"2014","unstructured":"Rothaug M, Zunke F, Mazzulli JR, Schweizer M, Altmeppen H, Lullmann-Rauch R, et al. LIMP-2 expression is critical for beta-glucocerebrosidase activity and alpha-synuclein clearance. Proc Natl Acad Sci U S A. 2014;111(43):15573\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"437_CR174","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13024-015-0010-2","volume":"10","author":"D Chiasserini","year":"2015","unstructured":"Chiasserini D, Paciotti S, Eusebi P, Persichetti E, Tasegian A, Kurzawa-Akanbi M, et al. Selective loss of glucocerebrosidase activity in sporadic Parkinson\u2019s disease and dementia with Lewy bodies. Mol Neurodegener. 2015;10:15.","journal-title":"Mol Neurodegener"},{"issue":"6","key":"437_CR175","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1002\/mds.25495","volume":"28","author":"KD van Dijk","year":"2013","unstructured":"van Dijk KD, Persichetti E, Chiasserini D, Eusebi P, Beccari T, Calabresi P, et al. Changes in endolysosomal enzyme activities in cerebrospinal fluid of patients with Parkinson\u2019s disease. Mov Disord. 2013;28(6):747\u201354.","journal-title":"Mov Disord"},{"issue":"8","key":"437_CR176","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1002\/mds.25772","volume":"29","author":"L Parnetti","year":"2014","unstructured":"Parnetti L, Chiasserini D, Persichetti E, Eusebi P, Varghese S, Qureshi MM, et al. Cerebrospinal fluid lysosomal enzymes and alpha-synuclein in Parkinson\u2019s disease. Mov Disord. 2014;29(8):1019\u201327.","journal-title":"Mov Disord"},{"issue":"10","key":"437_CR177","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1002\/mds.27136","volume":"32","author":"L Parnetti","year":"2017","unstructured":"Parnetti L, Paciotti S, Eusebi P, Dardis A, Zampieri S, Chiasserini D, et al. Cerebrospinal fluid beta-glucocerebrosidase activity is reduced in parkinson\u2019s disease patients. Mov Disord. 2017;32(10):1423\u201331.","journal-title":"Mov Disord"},{"issue":"4","key":"437_CR178","doi-asserted-by":"publisher","first-page":"e388","DOI":"10.1212\/WNL.0000000000201418","volume":"100","author":"L Oftedal","year":"2023","unstructured":"Oftedal L, Maple-Grodem J, Dalen I, Tysnes OB, Pedersen KF, Alves G, et al. Association of CSF glucocerebrosidase activity with the risk of incident Dementia in patients with Parkinson disease. Neurology. 2023;100(4):e388\u201395.","journal-title":"Neurology"},{"issue":"3","key":"437_CR179","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.nbd.2009.05.023","volume":"35","author":"Y Chu","year":"2009","unstructured":"Chu Y, Dodiya H, Aebischer P, Olanow CW, Kordower JH. Alterations in lysosomal and proteasomal markers in Parkinson\u2019s disease: relationship to alpha-synuclein inclusions. Neurobiol Dis. 2009;35(3):385\u201398.","journal-title":"Neurobiol Dis"},{"issue":"8","key":"437_CR180","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.3390\/cells11081261","volume":"11","author":"L Smith","year":"2022","unstructured":"Smith L, Schapira AHV. GBA variants and Parkinson disease: mechanisms and treatments. Cells. 2022;11(8):1261.","journal-title":"Cells"},{"issue":"13","key":"437_CR181","first-page":"2712","volume":"25","author":"G Maor","year":"2016","unstructured":"Maor G, Cabasso O, Krivoruk O, Rodriguez J, Steller H, Segal D, et al. The contribution of mutant GBA to the development of Parkinson disease in Drosophila. Hum Mol Genet. 2016;25(13):2712\u201327.","journal-title":"Hum Mol Genet"},{"key":"437_CR182","doi-asserted-by":"publisher","first-page":"4028","DOI":"10.1038\/ncomms5028","volume":"5","author":"DC Schondorf","year":"2014","unstructured":"Schondorf DC, Aureli M, McAllister FE, Hindley CJ, Mayer F, Schmid B, et al. iPSC-derived neurons from GBA1-associated Parkinson\u2019s disease patients show autophagic defects and impaired calcium homeostasis. Nat Commun. 2014;5:4028.","journal-title":"Nat Commun"},{"issue":"1","key":"437_CR183","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ceca.2015.11.002","volume":"59","author":"BS Kilpatrick","year":"2016","unstructured":"Kilpatrick BS, Magalhaes J, Beavan MS, McNeill A, Gegg ME, Cleeter MW, et al. Endoplasmic reticulum and lysosomal Ca(2)(+) stores are remodelled in GBA1-linked Parkinson disease patient fibroblasts. Cell Calcium. 2016;59(1):12\u201320.","journal-title":"Cell Calcium"},{"issue":"3","key":"437_CR184","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.stemcr.2016.01.013","volume":"6","author":"HJ Fernandes","year":"2016","unstructured":"Fernandes HJ, Hartfield EM, Christian HC, Emmanoulidou E, Zheng Y, Booth H, et al. ER stress and autophagic perturbations lead to elevated extracellular alpha-synuclein in GBA-N370S Parkinson\u2019s iPSC-derived dopamine neurons. Stem Cell Rep. 2016;6(3):342\u201356.","journal-title":"Stem Cell Rep"},{"key":"437_CR185","doi-asserted-by":"publisher","first-page":"31380","DOI":"10.1038\/srep31380","volume":"6","author":"A Sanchez-Martinez","year":"2016","unstructured":"Sanchez-Martinez A, Beavan M, Gegg ME, Chau KY, Whitworth AJ, Schapira AH. Parkinson disease-linked GBA mutation effects reversed by molecular chaperones in human cell and fly models. Sci Rep. 2016;6:31380.","journal-title":"Sci Rep"},{"issue":"10","key":"437_CR186","doi-asserted-by":"publisher","first-page":"2976","DOI":"10.1016\/j.celrep.2018.05.009","volume":"23","author":"DC Schondorf","year":"2018","unstructured":"Schondorf DC, Ivanyuk D, Baden P, Sanchez-Martinez A, De Cicco S, Yu C, et al. The NAD+ precursor nicotinamide riboside rescues mitochondrial defects and neuronal loss in iPSC and Fly models of Parkinson\u2019s disease. Cell Rep. 2018;23(10):2976\u201388.","journal-title":"Cell Rep"},{"issue":"3","key":"437_CR187","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/ana.23614","volume":"72","author":"ME Gegg","year":"2012","unstructured":"Gegg ME, Burke D, Heales SJ, Cooper JM, Hardy J, Wood NW, et al. Glucocerebrosidase deficiency in substantia nigra of Parkinson disease brains. Ann Neurol. 2012;72(3):455\u201363.","journal-title":"Ann Neurol"},{"issue":"1","key":"437_CR188","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/s41593-021-00989-0","volume":"25","author":"R Wright","year":"2022","unstructured":"Wright R. Mitochondrial dysfunction and Parkinson\u2019s disease. Nat Neurosci. 2022;25(1):2.","journal-title":"Nat Neurosci"},{"issue":"1","key":"437_CR189","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1038\/s41467-021-22113-3","volume":"12","author":"S Kim","year":"2021","unstructured":"Kim S, Wong YC, Gao F, Krainc D. Dysregulation of mitochondria-lysosome contacts by GBA1 dysfunction in dopaminergic neuronal models of Parkinson\u2019s disease. Nat Commun. 2021;12(1):1807.","journal-title":"Nat Commun"},{"issue":"1","key":"437_CR190","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1038\/s41467-023-37454-4","volume":"14","author":"P Baden","year":"2023","unstructured":"Baden P, Perez MJ, Raji H, Bertoli F, Kalb S, Illescas M, et al. Glucocerebrosidase is imported into mitochondria and preserves complex I integrity and energy metabolism. Nat Commun. 2023;14(1):1930.","journal-title":"Nat Commun"},{"key":"437_CR191","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1093\/brain\/awae070","volume":"147","author":"JC Rubilar","year":"2024","unstructured":"Rubilar JC, Outeiro TF, Klein AD. The lysosomal beta-glucocerebrosidase strikes mitochondria: implications for Parkinson\u2019s therapeutics. Brain. 2024;147:2610\u201320.","journal-title":"Brain"},{"issue":"1","key":"437_CR192","doi-asserted-by":"publisher","first-page":"6383","DOI":"10.1038\/s41467-023-42107-7","volume":"14","author":"AD Klein","year":"2023","unstructured":"Klein AD, Outeiro TF. Glucocerebrosidase mutations disrupt the lysosome and now the mitochondria. Nat Commun. 2023;14(1):6383.","journal-title":"Nat Commun"},{"issue":"1","key":"437_CR193","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neuint.2012.10.010","volume":"62","author":"MW Cleeter","year":"2013","unstructured":"Cleeter MW, Chau KY, Gluck C, Mehta A, Hughes DA, Duchen M, et al. Glucocerebrosidase inhibition causes mitochondrial dysfunction and free radical damage. Neurochem Int. 2013;62(1):1\u20137.","journal-title":"Neurochem Int"},{"key":"437_CR194","doi-asserted-by":"publisher","first-page":"10903","DOI":"10.1038\/srep10903","volume":"5","author":"M de la Mata","year":"2015","unstructured":"de la Mata M, Cotan D, Oropesa-Avila M, Garrido-Maraver J, Cordero MD, Villanueva Paz M, et al. Pharmacological chaperones and coenzyme Q10 treatment improves mutant beta-glucocerebrosidase activity and mitochondrial function in neuronopathic forms of gaucher disease. Sci Rep. 2015;5:10903.","journal-title":"Sci Rep"},{"issue":"6","key":"437_CR195","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.cmet.2013.04.014","volume":"17","author":"LD Osellame","year":"2013","unstructured":"Osellame LD, Rahim AA, Hargreaves IP, Gegg ME, Richard-Londt A, Brandner S, et al. Mitochondria and quality control defects in a mouse model of Gaucher disease\u2013links to Parkinson\u2019s disease. Cell Metab. 2013;17(6):941\u201353.","journal-title":"Cell Metab"},{"issue":"1","key":"437_CR196","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1080\/15548627.2018.1509818","volume":"15","author":"H Li","year":"2019","unstructured":"Li H, Ham A, Ma TC, Kuo SH, Kanter E, Kim D, et al. Mitochondrial dysfunction and mitophagy defect triggered by heterozygous GBA mutations. Autophagy. 2019;15(1):113\u201330.","journal-title":"Autophagy"},{"issue":"4","key":"437_CR197","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.tibs.2015.02.003","volume":"40","author":"BJ Ryan","year":"2015","unstructured":"Ryan BJ, Hoek S, Fon EA, Wade-Martins R. Mitochondrial dysfunction and mitophagy in Parkinson\u2019s: from familial to sporadic disease. Trends Biochem Sci. 2015;40(4):200\u201310.","journal-title":"Trends Biochem Sci"},{"issue":"4","key":"437_CR198","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.tibs.2020.11.007","volume":"46","author":"AB Malpartida","year":"2021","unstructured":"Malpartida AB, Williamson M, Narendra DP, Wade-Martins R, Ryan BJ. Mitochondrial dysfunction and mitophagy in Parkinson\u2019s disease: from mechanism to therapy. Trends Biochem Sci. 2021;46(4):329\u201343.","journal-title":"Trends Biochem Sci"},{"issue":"15","key":"437_CR199","doi-asserted-by":"publisher","first-page":"3943","DOI":"10.1093\/hmg\/ddu105","volume":"23","author":"YH Xu","year":"2014","unstructured":"Xu YH, Xu K, Sun Y, Liou B, Quinn B, Li RH, et al. Multiple pathogenic proteins implicated in neuronopathic Gaucher disease mice. Hum Mol Genet. 2014;23(15):3943\u201357.","journal-title":"Hum Mol Genet"},{"issue":"1","key":"437_CR200","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41531-023-00457-5","volume":"9","author":"L Munoz-Delgado","year":"2023","unstructured":"Munoz-Delgado L, Macias-Garcia D, Perinan MT, Jesus S, Adarmes-Gomez AD, Bonilla Toribio M, et al. Peripheral inflammatory immune response differs among sporadic and familial Parkinson\u2019s disease. NPJ Parkinsons Dis. 2023;9(1):12.","journal-title":"NPJ Parkinsons Dis"},{"issue":"7643","key":"437_CR201","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nature21368","volume":"543","author":"MK Pandey","year":"2017","unstructured":"Pandey MK, Burrow TA, Rani R, Martin LJ, Witte D, Setchell KD, et al. Complement drives glucosylceramide accumulation and tissue inflammation in Gaucher disease. Nature. 2017;543(7643):108\u201312.","journal-title":"Nature"},{"key":"437_CR202","doi-asserted-by":"publisher","first-page":"e79830","DOI":"10.7554\/eLife.79830","volume":"11","author":"CS Boddupalli","year":"2022","unstructured":"Boddupalli CS, Nair S, Belinsky G, Gans J, Teeple E, Nguyen TH, et al. Neuroinflammation in neuronopathic Gaucher disease: role of microglia and NK cells, biomarkers, and response to substrate reduction therapy. Elife. 2022;11:e79830.","journal-title":"Elife"},{"issue":"1","key":"437_CR203","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41572-018-0025-4","volume":"4","author":"FM Platt","year":"2018","unstructured":"Platt FM, d\u2019Azzo A, Davidson BL, Neufeld EF, Tifft CJ. Lysosomal storage diseases. Nat Rev Dis Primers. 2018;4(1):27.","journal-title":"Nat Rev Dis Primers"},{"issue":"6","key":"437_CR204","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1089\/ars.2015.6307","volume":"23","author":"EM Rocha","year":"2015","unstructured":"Rocha EM, Smith GA, Park E, Cao H, Graham AR, Brown E, et al. Sustained systemic glucocerebrosidase inhibition induces brain alpha-synuclein aggregation, microglia and complement C1q activation in mice. Antioxid Redox Signal. 2015;23(6):550\u201364.","journal-title":"Antioxid Redox Signal"},{"key":"437_CR205","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.nbd.2018.12.001","volume":"124","author":"L Mus","year":"2019","unstructured":"Mus L, Siani F, Giuliano C, Ghezzi C, Cerri S, Blandini F. Development and biochemical characterization of a mouse model of Parkinson\u2019s disease bearing defective glucocerebrosidase activity. Neurobiol Dis. 2019;124:289\u201396.","journal-title":"Neurobiol Dis"},{"issue":"15","key":"437_CR206","doi-asserted-by":"publisher","first-page":"12164","DOI":"10.3390\/ijms241512164","volume":"24","author":"T Usenko","year":"2023","unstructured":"Usenko T, Bezrukova A, Rudenok MM, Basharova K, Shadrina MI, Slominsky PA, et al. Whole transcriptome analysis of substantia Nigra in mice with MPTP-induced parkinsonism bearing defective glucocerebrosidase activity. Int J Mol Sci. 2023;24(15):12164.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"437_CR207","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s10517-020-04723-x","volume":"168","author":"IV Miliukhina","year":"2020","unstructured":"Miliukhina IV, Usenko TS, Senkevich KA, Nikolaev MA, Timofeeva AA, Agapova EA, et al. Plasma cytokines profile in patients with Parkinson\u2019s disease associated with mutations in GBA gene. Bull Exp Biol Med. 2020;168(4):423\u20136.","journal-title":"Bull Exp Biol Med"},{"issue":"7","key":"437_CR208","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1001\/jamaneurol.2013.1274","volume":"70","author":"LM Chahine","year":"2013","unstructured":"Chahine LM, Qiang J, Ashbridge E, Minger J, Yearout D, Horn S, et al. Clinical and biochemical differences in patients having Parkinson disease with vs without GBA mutations. JAMA Neurol. 2013;70(7):852\u20138.","journal-title":"JAMA Neurol"},{"issue":"1","key":"437_CR209","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/acel.12409","volume":"15","author":"E Aflaki","year":"2016","unstructured":"Aflaki E, Moaven N, Borger DK, Lopez G, Westbroek W, Chae JJ, et al. Lysosomal storage and impaired autophagy lead to inflammasome activation in Gaucher macrophages. Aging Cell. 2016;15(1):77\u201388.","journal-title":"Aging Cell"},{"key":"437_CR210","doi-asserted-by":"publisher","first-page":"108964","DOI":"10.1016\/j.neuropharm.2022.108964","volume":"207","author":"RX Bo","year":"2022","unstructured":"Bo RX, Li YY, Zhou TT, Chen NH, Yuan YH. The neuroinflammatory role of glucocerebrosidase in Parkinson\u2019s disease. Neuropharmacology. 2022;207:108964.","journal-title":"Neuropharmacology"},{"key":"437_CR211","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.nbd.2018.03.008","volume":"122","author":"C Pitcairn","year":"2019","unstructured":"Pitcairn C, Wani WY, Mazzulli JR. Dysregulation of the autophagic-lysosomal pathway in Gaucher and Parkinson\u2019s disease. Neurobiol Dis. 2019;122:72\u201382.","journal-title":"Neurobiol Dis"},{"issue":"11","key":"437_CR212","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.3390\/genes13111937","volume":"13","author":"J Kim","year":"2022","unstructured":"Kim J, Daadi EW, Oh T, Daadi ES, Daadi MM. Human induced pluripotent stem cell phenotyping and preclinical modeling of familial Parkinson\u2019s disease. Genes (Basel). 2022;13(11):1937.","journal-title":"Genes (Basel)"},{"issue":"1","key":"437_CR213","doi-asserted-by":"publisher","first-page":"327","DOI":"10.3390\/ijms25010327","volume":"25","author":"ES Yarkova","year":"2023","unstructured":"Yarkova ES, Grigor\u2019eva EV, Medvedev SP, Pavlova SV, Zakian SM, Malakhova AA. IPSC-derived astrocytes contribute to in vitro modeling of Parkinson\u2019s disease caused by the GBA1 N370S mutation. Int J Mol Sci. 2023;25(1):327.","journal-title":"Int J Mol Sci"},{"issue":"11","key":"437_CR214","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1038\/s41582-022-00723-9","volume":"18","author":"OL Eichmuller","year":"2022","unstructured":"Eichmuller OL, Knoblich JA. Human cerebral organoids\u2014a new tool for clinical neurology research. Nat Rev Neurol. 2022;18(11):661\u201380.","journal-title":"Nat Rev Neurol"},{"issue":"2","key":"437_CR215","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.ajhg.2021.12.009","volume":"109","author":"A Zagare","year":"2022","unstructured":"Zagare A, Barmpa K, Smajic S, Smits LM, Grzyb K, Grunewald A, et al. Midbrain organoids mimic early embryonic neurodevelopment and recapitulate LRRK2-p.Gly2019Ser-associated gene expression. Am J Hum Genet. 2022;109(2):311\u201327.","journal-title":"Am J Hum Genet"},{"issue":"7","key":"437_CR216","doi-asserted-by":"publisher","first-page":"6338","DOI":"10.3390\/ijms24076338","volume":"24","author":"V Yahya","year":"2023","unstructured":"Yahya V, Di Fonzo A, Monfrini E. Genetic evidence for endolysosomal dysfunction in Parkinson\u2019s disease: a critical overview. Int J Mol Sci. 2023;24(7):6338.","journal-title":"Int J Mol Sci"},{"key":"437_CR217","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.conb.2021.09.004","volume":"72","author":"M Sanchiz-Calvo","year":"2022","unstructured":"Sanchiz-Calvo M, Bentea E, Baekelandt V. Rodent models based on endolysosomal genes involved in Parkinson\u2019s disease. Curr Opin Neurobiol. 2022;72:55\u201362.","journal-title":"Curr Opin Neurobiol"},{"issue":"10","key":"437_CR218","doi-asserted-by":"publisher","first-page":"2706","DOI":"10.1093\/brain\/awx221","volume":"140","author":"A Migdalska-Richards","year":"2017","unstructured":"Migdalska-Richards A, Wegrzynowicz M, Rusconi R, Deangeli G, Di Monte DA, Spillantini MG, et al. The L444P Gba1 mutation enhances alpha-synuclein induced loss of nigral dopaminergic neurons in mice. Brain. 2017;140(10):2706\u201321.","journal-title":"Brain"},{"issue":"8","key":"437_CR219","doi-asserted-by":"publisher","first-page":"e0238075","DOI":"10.1371\/journal.pone.0238075","volume":"15","author":"A Migdalska-Richards","year":"2020","unstructured":"Migdalska-Richards A, Wegrzynowicz M, Harrison IF, Verona G, Bellotti V, Spillantini MG, et al. L444P Gba1 mutation increases formation and spread of alpha-synuclein deposits in mice injected with mouse alpha-synuclein pre-formed fibrils. PLoS ONE. 2020;15(8):e0238075.","journal-title":"PLoS ONE"},{"issue":"1","key":"437_CR220","doi-asserted-by":"publisher","first-page":"e2210442120","DOI":"10.1073\/pnas.2210442120","volume":"120","author":"X Zhao","year":"2023","unstructured":"Zhao X, Lin Y, Liou B, Fu W, Jian J, Fannie V, et al. PGRN deficiency exacerbates, whereas a brain penetrant PGRN derivative protects, GBA1 mutation-associated pathologies and diseases. Proc Natl Acad Sci U S A. 2023;120(1):e2210442120.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"Pt 9","key":"437_CR221","doi-asserted-by":"publisher","first-page":"2648","DOI":"10.1093\/brain\/awv179","volume":"138","author":"RN Alcalay","year":"2015","unstructured":"Alcalay RN, Levy OA, Waters CC, Fahn S, Ford B, Kuo SH, et al. Glucocerebrosidase activity in Parkinson\u2019s disease with and without GBA mutations. Brain. 2015;138(Pt 9):2648\u201358.","journal-title":"Brain"},{"issue":"6","key":"437_CR222","doi-asserted-by":"publisher","first-page":"e685","DOI":"10.1212\/WNL.0000000000009989","volume":"95","author":"YE Huh","year":"2020","unstructured":"Huh YE, Chiang MSR, Locascio JJ, Liao Z, Liu G, Choudhury K, et al. beta-Glucocerebrosidase activity in GBA-linked Parkinson disease: the type of mutation matters. Neurology. 2020;95(6):e685\u201396.","journal-title":"Neurology"},{"issue":"3","key":"437_CR223","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1615\/CritRevOncog.2013006060","volume":"18","author":"BE Rosenbloom","year":"2013","unstructured":"Rosenbloom BE, Weinreb NJ. Gaucher disease: a comprehensive review. Crit Rev Oncog. 2013;18(3):163\u201375.","journal-title":"Crit Rev Oncog"},{"issue":"1","key":"437_CR224","doi-asserted-by":"publisher","first-page":"15446","DOI":"10.1038\/s41598-018-33921-x","volume":"8","author":"F Atashrazm","year":"2018","unstructured":"Atashrazm F, Hammond D, Perera G, Dobson-Stone C, Mueller N, Pickford R, et al. Reduced glucocerebrosidase activity in monocytes from patients with Parkinson\u2019s disease. Sci Rep. 2018;8(1):15446.","journal-title":"Sci Rep"},{"issue":"1","key":"437_CR225","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41531-022-00354-3","volume":"8","author":"M Kedariti","year":"2022","unstructured":"Kedariti M, Frattini E, Baden P, Cogo S, Civiero L, Ziviani E, et al. LRRK2 kinase activity regulates GCase level and enzymatic activity differently depending on cell type in Parkinson\u2019s disease. NPJ Parkinsons Dis. 2022;8(1):92.","journal-title":"NPJ Parkinsons Dis"},{"issue":"4","key":"437_CR226","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1038\/nn.3350","volume":"16","author":"SJ Orenstein","year":"2013","unstructured":"Orenstein SJ, Kuo SH, Tasset I, Arias E, Koga H, Fernandez-Carasa I, et al. Interplay of LRRK2 with chaperone-mediated autophagy. Nat Neurosci. 2013;16(4):394\u2013406.","journal-title":"Nat Neurosci"},{"issue":"3","key":"437_CR227","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.neuron.2012.11.033","volume":"77","author":"DA MacLeod","year":"2013","unstructured":"MacLeod DA, Rhinn H, Kuwahara T, Zolin A, Di Paolo G, McCabe BD, et al. RAB7L1 interacts with LRRK2 to modify intraneuronal protein sorting and Parkinson\u2019s disease risk. Neuron. 2013;77(3):425\u201339.","journal-title":"Neuron"},{"issue":"10","key":"437_CR228","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1002\/mds.29163","volume":"37","author":"D Te Vruchte","year":"2022","unstructured":"Te Vruchte D, Sturchio A, Priestman DA, Tsitsi P, Hertz E, Andreasson M, et al. Glycosphingolipid changes in plasma in Parkinson\u2019s disease independent of glucosylceramide levels. Mov Disord. 2022;37(10):2129\u201334.","journal-title":"Mov Disord"},{"issue":"1","key":"437_CR229","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13024-019-0339-z","volume":"14","author":"M Huebecker","year":"2019","unstructured":"Huebecker M, Moloney EB, van der Spoel AC, Priestman DA, Isacson O, Hallett PJ, et al. Reduced sphingolipid hydrolase activities, substrate accumulation and ganglioside decline in Parkinson\u2019s disease. Mol Neurodegener. 2019;14(1):40.","journal-title":"Mol Neurodegener"},{"issue":"2","key":"437_CR230","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1002\/mds.28846","volume":"37","author":"M Surface","year":"2022","unstructured":"Surface M, Balwani M, Waters C, Haimovich A, Gan-Or Z, Marder KS, et al. Plasma glucosylsphingosine in GBA1 mutation carriers with and without Parkinson\u2019s disease. Mov Disord. 2022;37(2):416\u201321.","journal-title":"Mov Disord"},{"issue":"4","key":"437_CR231","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1002\/acn3.177","volume":"2","author":"EM Rocha","year":"2015","unstructured":"Rocha EM, Smith GA, Park E, Cao H, Brown E, Hallett P, et al. Progressive decline of glucocerebrosidase in aging and Parkinson\u2019s disease. Ann Clin Transl Neurol. 2015;2(4):433\u20138.","journal-title":"Ann Clin Transl Neurol"},{"issue":"1","key":"437_CR232","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/s41531-022-00363-2","volume":"8","author":"S Blumenreich","year":"2022","unstructured":"Blumenreich S, Nehushtan T, Barav OB, Saville JT, Dingjan T, Hardy J, et al. Elevation of gangliosides in four brain regions from Parkinson\u2019s disease patients with a GBA mutation. NPJ Parkinsons Dis. 2022;8(1):99.","journal-title":"NPJ Parkinsons Dis"},{"issue":"1","key":"437_CR233","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/s41531-021-00241-3","volume":"7","author":"YE Huh","year":"2021","unstructured":"Huh YE, Park H, Chiang MSR, Tuncali I, Liu G, Locascio JJ, et al. Glucosylceramide in cerebrospinal fluid of patients with GBA-associated and idiopathic Parkinson\u2019s disease enrolled in PPMI. NPJ Parkinsons Dis. 2021;7(1):102.","journal-title":"NPJ Parkinsons Dis"},{"issue":"12","key":"437_CR234","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1002\/mds.28815","volume":"36","author":"D Ysselstein","year":"2021","unstructured":"Ysselstein D, Young TJ, Nguyen M, Padmanabhan S, Hirst WD, Dzamko N, et al. Evaluation of strategies for measuring lysosomal glucocerebrosidase activity. Mov Disord. 2021;36(12):2719\u201330.","journal-title":"Mov Disord"},{"issue":"1","key":"437_CR235","doi-asserted-by":"publisher","first-page":"22098","DOI":"10.1038\/s41598-020-79104-5","volume":"10","author":"L Oftedal","year":"2020","unstructured":"Oftedal L, Maple-Grodem J, Forland MGG, Alves G, Lange J. Validation and assessment of preanalytical factors of a fluorometric in vitro assay for glucocerebrosidase activity in human cerebrospinal fluid. Sci Rep. 2020;10(1):22098.","journal-title":"Sci Rep"},{"issue":"9","key":"437_CR236","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.tins.2019.05.010","volume":"42","author":"T Farfel-Becker","year":"2019","unstructured":"Farfel-Becker T, Do J, Tayebi N, Sidransky E. Can GBA1-associated Parkinson disease be modeled in the mouse? Trends Neurosci. 2019;42(9):631\u201343.","journal-title":"Trends Neurosci"},{"key":"437_CR237","doi-asserted-by":"publisher","first-page":"142 e1","DOI":"10.1016\/j.neurobiolaging.2021.02.018","volume":"103","author":"YL Sosero","year":"2021","unstructured":"Sosero YL, Yu E, Krohn L, Rudakou U, Mufti K, Ruskey JA, et al. LRRK2 p.M1646T is associated with glucocerebrosidase activity and with Parkinson\u2019s disease. Neurobiol Aging. 2021;103:142 e1-142 e5.","journal-title":"Neurobiol Aging"},{"issue":"3","key":"437_CR238","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/s41589-021-00960-x","volume":"18","author":"S Cecioni","year":"2022","unstructured":"Cecioni S, Ashmus RA, Gilormini PA, Zhu S, Chen X, Shan X, et al. Quantifying lysosomal glycosidase activity within cells using bis-acetal substrates. Nat Chem Biol. 2022;18(3):332\u201341.","journal-title":"Nat Chem Biol"},{"key":"437_CR239","doi-asserted-by":"publisher","first-page":"108822","DOI":"10.1016\/j.neuropharm.2021.108822","volume":"202","author":"K Senkevich","year":"2022","unstructured":"Senkevich K, Rudakou U, Gan-Or Z. New therapeutic approaches to Parkinson\u2019s disease targeting GBA, LRRK2 and Parkin. Neuropharmacology. 2022;202:108822.","journal-title":"Neuropharmacology"},{"issue":"10","key":"437_CR240","doi-asserted-by":"publisher","first-page":"2699","DOI":"10.1073\/pnas.1616152114","volume":"114","author":"SP Sardi","year":"2017","unstructured":"Sardi SP, Viel C, Clarke J, Treleaven CM, Richards AM, Park H, et al. Glucosylceramide synthase inhibition alleviates aberrations in synucleinopathy models. Proc Natl Acad Sci U S A. 2017;114(10):2699\u2013704.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"437_CR241","doi-asserted-by":"publisher","first-page":"20945","DOI":"10.1038\/s41598-021-00404-5","volume":"11","author":"C Viel","year":"2021","unstructured":"Viel C, Clarke J, Kayatekin C, Richards AM, Chiang MSR, Park H, et al. Preclinical pharmacology of glucosylceramide synthase inhibitor venglustat in a GBA-related synucleinopathy model. Sci Rep. 2021;11(1):20945.","journal-title":"Sci Rep"},{"issue":"8","key":"437_CR242","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/S1474-4422(23)00205-3","volume":"22","author":"N Giladi","year":"2023","unstructured":"Giladi N, Alcalay RN, Cutter G, Gasser T, Gurevich T, Hoglinger GU, et al. Safety and efficacy of venglustat in GBA1-associated Parkinson\u2019s disease: an international, multicentre, double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2023;22(8):661\u201371.","journal-title":"Lancet Neurol"},{"issue":"2","key":"437_CR243","doi-asserted-by":"publisher","first-page":"557","DOI":"10.3233\/JPD-212714","volume":"12","author":"MJ Peterschmitt","year":"2022","unstructured":"Peterschmitt MJ, Saiki H, Hatano T, Gasser T, Isaacson SH, Gaemers SJM, et al. Safety, pharmacokinetics, and pharmacodynamics of oral venglustat in patients with Parkinson\u2019s disease and a GBA mutation: results from part 1 of the randomized, double-blinded, placebo-controlled MOVES-PD trial. J Parkinsons Dis. 2022;12(2):557\u201370.","journal-title":"J Parkinsons Dis"},{"issue":"3","key":"437_CR244","doi-asserted-by":"publisher","first-page":"261","DOI":"10.14802\/jmd.23023","volume":"16","author":"YE Huh","year":"2023","unstructured":"Huh YE, Usnich T, Scherzer CR, Klein C, Chung SJ. GBA1 variants and Parkinson\u2019s disease: paving the way for targeted therapy. J Mov Disord. 2023;16(3):261\u201378.","journal-title":"J Mov Disord"},{"issue":"2","key":"437_CR245","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/S1474-4422(23)00455-6","volume":"23","author":"A Zimran","year":"2024","unstructured":"Zimran A, Revel-Vilk S, Becker-Cohen M, Istaiti M, Rolfs A. Venglustat in GBA1-related Parkinson\u2019s disease. Lancet Neurol. 2024;23(2):137.","journal-title":"Lancet Neurol"},{"issue":"5","key":"437_CR246","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1002\/ajh.26131","volume":"96","author":"M Istaiti","year":"2021","unstructured":"Istaiti M, Revel-Vilk S, Becker-Cohen M, Dinur T, Ramaswami U, Castillo-Garcia D, et al. Upgrading the evidence for the use of ambroxol in Gaucher disease and GBA related Parkinson: investigator initiated registry based on real life data. Am J Hematol. 2021;96(5):545\u201351.","journal-title":"Am J Hematol"},{"issue":"38","key":"437_CR247","doi-asserted-by":"publisher","first-page":"e202207974","DOI":"10.1002\/anie.202207974","volume":"61","author":"AG Santana","year":"2022","unstructured":"Santana AG, Robinson K, Vickers C, Deen MC, Chen HM, Zhou S, et al. Pharmacological chaperones for GCase that switch conformation with pH enhance enzyme levels in Gaucher animal models. Angew Chem Int Ed Engl. 2022;61(38):e202207974.","journal-title":"Angew Chem Int Ed Engl"},{"issue":"10","key":"437_CR248","doi-asserted-by":"publisher","first-page":"3015","DOI":"10.1016\/j.apsb.2021.02.016","volume":"11","author":"K Zhang","year":"2021","unstructured":"Zhang K, Zhu S, Li J, Jiang T, Feng L, Pei J, et al. Targeting autophagy using small-molecule compounds to improve potential therapy of Parkinson\u2019s disease. Acta Pharm Sin B. 2021;11(10):3015\u201334.","journal-title":"Acta Pharm Sin B"},{"issue":"7","key":"437_CR249","doi-asserted-by":"publisher","first-page":"823","DOI":"10.3390\/ph15070823","volume":"15","author":"M Martinez-Bailen","year":"2022","unstructured":"Martinez-Bailen M, Clemente F, Matassini C, Cardona F. GCase enhancers: a potential therapeutic option for gaucher disease and other neurological disorders. Pharmaceuticals (Basel). 2022;15(7):823.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"10","key":"437_CR250","doi-asserted-by":"publisher","first-page":"9105","DOI":"10.3390\/ijms24109105","volume":"24","author":"AE Kopytova","year":"2023","unstructured":"Kopytova AE, Rychkov GN, Cheblokov AA, Grigor\u2019eva EV, Nikolaev MA, Yarkova ES, et al. Potential binding sites of pharmacological chaperone NCGC00241607 on mutant beta-glucocerebrosidase and its efficacy on patient-derived cell cultures in gaucher and Parkinson\u2019s disease. Int J Mol Sci. 2023;24(10):9105.","journal-title":"Int J Mol Sci"},{"key":"437_CR251","doi-asserted-by":"publisher","first-page":"271","DOI":"10.3389\/fcell.2020.00271","volume":"8","author":"TU Han","year":"2020","unstructured":"Han TU, Sam R, Sidransky E. Small molecule chaperones for the treatment of Gaucher disease and GBA1-associated Parkinson disease. Front Cell Dev Biol. 2020;8:271.","journal-title":"Front Cell Dev Biol"},{"issue":"514","key":"437_CR252","doi-asserted-by":"publisher","first-page":"eaau6870","DOI":"10.1126\/scitranslmed.aau6870","volume":"11","author":"LF Burbulla","year":"2019","unstructured":"Burbulla LF, Jeon S, Zheng J, Song P, Silverman RB, Krainc D. A modulator of wild-type glucocerebrosidase improves pathogenic phenotypes in dopaminergic neuronal models of Parkinson's disease. Sci Transl Med. 2019;11(514):eaau6870.","journal-title":"Sci Transl Med"},{"issue":"4","key":"437_CR253","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1001\/jamaneurol.2019.4611","volume":"77","author":"S Mullin","year":"2020","unstructured":"Mullin S, Smith L, Lee K, D\u2019Souza G, Woodgate P, Elflein J, et al. Ambroxol for the treatment of patients with Parkinson disease with and without glucocerebrosidase gene mutations: a nonrandomized, noncontrolled trial. JAMA Neurol. 2020;77(4):427\u201334.","journal-title":"JAMA Neurol"},{"issue":"14","key":"437_CR254","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1093\/hmg\/ddac038","volume":"31","author":"SY Yang","year":"2022","unstructured":"Yang SY, Taanman JW, Gegg M, Schapira AHV. Ambroxol reverses tau and alpha-synuclein accumulation in a cholinergic N370S GBA1 mutation model. Hum Mol Genet. 2022;31(14):2396\u2013405.","journal-title":"Hum Mol Genet"},{"issue":"1","key":"437_CR255","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s12883-024-03629-9","volume":"24","author":"O Siemeling","year":"2024","unstructured":"Siemeling O, Slingerland S, van der Zee S, van Laar T. Study protocol of the GRoningen early-PD Ambroxol treatment (GREAT) trial: a randomized, double-blind, placebo-controlled, single center trial with ambroxol in Parkinson patients with a GBA mutation. BMC Neurol. 2024;24(1):146.","journal-title":"BMC Neurol"},{"key":"437_CR256","doi-asserted-by":"publisher","first-page":"105774","DOI":"10.1016\/j.neuint.2024.105774","volume":"178","author":"Z Cyske","year":"2024","unstructured":"Cyske Z, Gaffke L, Rintz E, Wisniewska K, Wegrzyn G, Pierzynowska K. Molecular mechanisms of the ambroxol action in Gaucher disease and GBA1 mutation-associated Parkinson disease. Neurochem Int. 2024;178:105774.","journal-title":"Neurochem Int"},{"issue":"Pt 5","key":"437_CR257","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1093\/brain\/awu020","volume":"137","author":"A McNeill","year":"2014","unstructured":"McNeill A, Magalhaes J, Shen C, Chau KY, Hughes D, Mehta A, et al. Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells. Brain. 2014;137(Pt 5):1481\u201395.","journal-title":"Brain"},{"key":"437_CR258","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.nbd.2015.06.008","volume":"82","author":"G Ambrosi","year":"2015","unstructured":"Ambrosi G, Ghezzi C, Zangaglia R, Levandis G, Pacchetti C, Blandini F. Ambroxol-induced rescue of defective glucocerebrosidase is associated with increased LIMP-2 and saposin C levels in GBA1 mutant Parkinson\u2019s disease cells. Neurobiol Dis. 2015;82:235\u201342.","journal-title":"Neurobiol Dis"},{"issue":"1","key":"437_CR259","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1038\/s41598-018-19479-8","volume":"8","author":"J Magalhaes","year":"2018","unstructured":"Magalhaes J, Gegg ME, Migdalska-Richards A, Schapira AH. Effects of ambroxol on the autophagy-lysosome pathway and mitochondria in primary cortical neurons. Sci Rep. 2018;8(1):1385.","journal-title":"Sci Rep"},{"issue":"3","key":"437_CR260","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s00210-019-01737-9","volume":"393","author":"A Mishra","year":"2020","unstructured":"Mishra A, Krishnamurthy S. Neurorestorative effects of sub-chronic administration of ambroxol in rodent model of Parkinson\u2019s disease. Naunyn Schmiedebergs Arch Pharmacol. 2020;393(3):429\u201344.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"5","key":"437_CR261","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1002\/ana.24790","volume":"80","author":"A Migdalska-Richards","year":"2016","unstructured":"Migdalska-Richards A, Daly L, Bezard E, Schapira AH. Ambroxol effects in glucocerebrosidase and alpha-synuclein transgenic mice. Ann Neurol. 2016;80(5):766\u201375.","journal-title":"Ann Neurol"},{"issue":"9","key":"437_CR262","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1007\/s00702-022-02531-3","volume":"129","author":"SRL Vieira","year":"2022","unstructured":"Vieira SRL, Schapira AHV. Glucocerebrosidase mutations and Parkinson disease. J Neural Transm (Vienna). 2022;129(9):1105\u201317.","journal-title":"J Neural Transm (Vienna)"},{"issue":"1","key":"437_CR263","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/jnc.14968","volume":"154","author":"M Toffoli","year":"2020","unstructured":"Toffoli M, Smith L, Schapira AHV. The biochemical basis of interactions between glucocerebrosidase and alpha-synuclein in GBA1 mutation carriers. J Neurochem. 2020;154(1):11\u201324.","journal-title":"J Neurochem"},{"issue":"2","key":"437_CR264","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.stem.2022.01.007","volume":"29","author":"H Okano","year":"2022","unstructured":"Okano H, Morimoto S. iPSC-based disease modeling and drug discovery in cardinal neurodegenerative disorders. Cell Stem Cell. 2022;29(2):189\u2013208.","journal-title":"Cell Stem Cell"},{"key":"437_CR265","doi-asserted-by":"publisher","first-page":"102114","DOI":"10.1016\/j.arr.2023.102114","volume":"92","author":"HM Mansour","year":"2023","unstructured":"Mansour HM, El-Khatib AS. Exploring Parkinson-associated kinases for CRISPR\/Cas9-based gene editing: beyond alpha-synuclein. Ageing Res Rev. 2023;92:102114.","journal-title":"Ageing Res Rev"},{"issue":"7","key":"437_CR266","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/j.stem.2023.05.015","volume":"30","author":"MS Kim","year":"2023","unstructured":"Kim MS, Ra EA, Kweon SH, Seo BA, Ko HS, Oh Y, et al. Advanced human iPSC-based preclinical model for Parkinson\u2019s disease with optogenetic alpha-synuclein aggregation. Cell Stem Cell. 2023;30(7):973-986 e11.","journal-title":"Cell Stem Cell"},{"key":"437_CR267","doi-asserted-by":"crossref","unstructured":"Kim MJ, Kim S, Reinheckel T, Krainc D. Inhibition of cysteine protease cathepsin Lincreases the level and activity of lysosomal glucocerebrosidase. JCI Insight. 2024;9(3).","DOI":"10.1172\/jci.insight.169594"},{"issue":"1","key":"437_CR268","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1038\/s41467-023-37632-4","volume":"14","author":"A Gehrlein","year":"2023","unstructured":"Gehrlein A, Udayar V, Anastasi N, Morella ML, Ruf I, Brugger D, et al. Targeting neuronal lysosomal dysfunction caused by beta-glucocerebrosidase deficiency with an enzyme-based brain shuttle construct. Nat Commun. 2023;14(1):2057.","journal-title":"Nat Commun"},{"issue":"12","key":"437_CR269","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1080\/14728222.2022.2166828","volume":"26","author":"C Chen","year":"2022","unstructured":"Chen C, Hertz E, Chen Y, Sidransky E. Targeting protein clearance pathways in GBA1-associated Parkinson disease. Expert Opin Ther Targets. 2022;26(12):1031\u20135.","journal-title":"Expert Opin Ther Targets"},{"issue":"4","key":"437_CR270","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1097\/WCO.0000000000000715","volume":"32","author":"E Ryan","year":"2019","unstructured":"Ryan E, Seehra G, Sharma P, Sidransky E. GBA1-associated Parkinsonism: new insights and therapeutic opportunities. Curr Opin Neurol. 2019;32(4):589\u201396.","journal-title":"Curr Opin Neurol"},{"key":"437_CR271","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.omtm.2023.03.007","volume":"29","author":"Y Peng","year":"2023","unstructured":"Peng Y, Liou B, Lin Y, Mayhew CN, Fleming SM, Sun Y. iPSC-derived neural precursor cells engineering GBA1 recovers acid beta-glucosidase deficiency and diminishes alpha-synuclein and neuropathology. Mol Ther Methods Clin Dev. 2023;29:185\u2013201.","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"3","key":"437_CR272","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1002\/ana.26166","volume":"90","author":"J Jo","year":"2021","unstructured":"Jo J, Yang L, Tran HD, Yu W, Sun AX, Chang YY, et al. Lewy body-like inclusions in human midbrain organoids carrying glucocerebrosidase and alpha-synuclein mutations. Ann Neurol. 2021;90(3):490\u2013505.","journal-title":"Ann Neurol"},{"issue":"10","key":"437_CR273","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1093\/hmg\/ddaa085","volume":"29","author":"ME Gegg","year":"2020","unstructured":"Gegg ME, Verona G, Schapira AHV. Glucocerebrosidase deficiency promotes release of alpha-synuclein fibrils from cultured neurons. Hum Mol Genet. 2020;29(10):1716\u201328.","journal-title":"Hum Mol Genet"},{"key":"437_CR274","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.nbd.2019.01.023","volume":"127","author":"P Baden","year":"2019","unstructured":"Baden P, Yu C, Deleidi M. Insights into GBA Parkinson\u2019s disease pathology and therapy with induced pluripotent stem cell model systems. Neurobiol Dis. 2019;127:1\u201312.","journal-title":"Neurobiol Dis"},{"key":"437_CR275","doi-asserted-by":"publisher","first-page":"135093","DOI":"10.1016\/j.neulet.2020.135093","volume":"733","author":"W Yang","year":"2020","unstructured":"Yang W, Li X, Yin N. Increased alpha-synuclein oligomerization is associated with decreased activity of glucocerebrosidase in the aging human striatum and hippocampus. Neurosci Lett. 2020;733:135093.","journal-title":"Neurosci Lett"},{"issue":"1","key":"437_CR276","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13024-017-0149-0","volume":"12","author":"H Xicoy","year":"2017","unstructured":"Xicoy H, Wieringa B, Martens GJ. The SH-SY5Y cell line in Parkinson\u2019s disease research: a systematic review. Mol Neurodegener. 2017;12(1):10.","journal-title":"Mol Neurodegener"},{"key":"437_CR277","doi-asserted-by":"publisher","first-page":"4755","DOI":"10.1038\/ncomms5755","volume":"5","author":"EJ Bae","year":"2014","unstructured":"Bae EJ, Yang NY, Song M, Lee CS, Lee JS, Jung BC, et al. Glucocerebrosidase depletion enhances cell-to-cell transmission of alpha-synuclein. Nat Commun. 2014;5:4755.","journal-title":"Nat Commun"},{"issue":"3","key":"437_CR278","doi-asserted-by":"publisher","first-page":"e153","DOI":"10.1038\/emm.2014.128","volume":"47","author":"EJ Bae","year":"2015","unstructured":"Bae EJ, Yang NY, Lee C, Lee HJ, Kim S, Sardi SP, et al. Loss of glucocerebrosidase 1 activity causes lysosomal dysfunction and alpha-synuclein aggregation. Exp Mol Med. 2015;47(3):e153.","journal-title":"Exp Mol Med"},{"issue":"Pt 12","key":"437_CR279","doi-asserted-by":"publisher","first-page":"3235","DOI":"10.1093\/brain\/awu291","volume":"137","author":"I Fishbein","year":"2014","unstructured":"Fishbein I, Kuo YM, Giasson BI, Nussbaum RL. Augmentation of phenotype in a transgenic Parkinson mouse heterozygous for a Gaucher mutation. Brain. 2014;137(Pt 12):3235\u201347.","journal-title":"Brain"},{"issue":"10","key":"437_CR280","first-page":"1696","volume":"27","author":"VE Papadopoulos","year":"2018","unstructured":"Papadopoulos VE, Nikolopoulou G, Antoniadou I, Karachaliou A, Arianoglou G, Emmanouilidou E, et al. Modulation of beta-glucocerebrosidase increases alpha-synuclein secretion and exosome release in mouse models of Parkinson\u2019s disease. Hum Mol Genet. 2018;27(10):1696\u2013710.","journal-title":"Hum Mol Genet"},{"issue":"9","key":"437_CR281","doi-asserted-by":"publisher","first-page":"3537","DOI":"10.1073\/pnas.1220464110","volume":"110","author":"SP Sardi","year":"2013","unstructured":"Sardi SP, Clarke J, Viel C, Chan M, Tamsett TJ, Treleaven CM, et al. Augmenting CNS glucocerebrosidase activity as a therapeutic strategy for parkinsonism and other Gaucher-related synucleinopathies. Proc Natl Acad Sci U S A. 2013;110(9):3537\u201342.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"437_CR282","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neuint.2013.04.005","volume":"63","author":"YN Deng","year":"2013","unstructured":"Deng YN, Shi J, Liu J, Qu QM. Celastrol protects human neuroblastoma SH-SY5Y cells from rotenone-induced injury through induction of autophagy. Neurochem Int. 2013;63(1):1\u20139.","journal-title":"Neurochem Int"}],"container-title":["Translational Neurodegeneration"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40035-024-00437-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40035-024-00437-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40035-024-00437-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T01:03:33Z","timestamp":1726103013000},"score":1,"resource":{"primary":{"URL":"https:\/\/translationalneurodegeneration.biomedcentral.com\/articles\/10.1186\/s40035-024-00437-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,12]]},"references-count":282,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["437"],"URL":"https:\/\/doi.org\/10.1186\/s40035-024-00437-6","relation":{},"ISSN":["2047-9158"],"issn-type":[{"value":"2047-9158","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,12]]},"assertion":[{"value":"29 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"48"}}